a. personal information - denver, colorado€¦ · a. personal information ... certificate in...

Curriculum Vitae Robert Lee Page II, Pharm. D.,

MSPH, FCCP, FAHA, FASHP, FASCP, BCPS, CGP

A. PERSONAL INFORMATION

Business Address: University of Colorado Anschutz Medical Campus

Skaggs School of Pharmacy and Pharmaceutical Sciences

Department of Clinical Pharmacy

Mail Stop C238

12850 E. Montview Blvd., V20-1127A

Aurora, CO 80045 Phone: 720-724-2626

e-mail: [email protected]

Home Address: 7665 East Gunnison Place

Denver, Colorado 80231

Phone: (303) 751-4474

Date of Birth: Farmville, Virginia June 14, 1969

B. EDUCATION AND TRAINING

Doctor of Philosophy (student) Colorado School of Public Health 2009-Present

Health Services Research Aurora, Colorado

Masters of Science University of Colorado Denver 2007-2009

in Public Health Graduate School

(Epidemiology-focus) Aurora, Colorado

Certificate in Public Health University of Colorado 2005-2007

School of Medicine

Denver, Colorado

Residency, Pharmacotherapy Medical University of South Carolina 1996-1998

Practice ACCP-ASHP Accredited Program

Charleston, South Carolina

Doctor of Pharmacy Medical University of South Carolina 1994 - 1996


Bachelor of Science in Medical University of South Carolina 1991 - 1994

Pharmacy Magna cum Laude, Second Honor Graduate


Bachelor of Science in Furman University 1987 - 1991

Biology/Chemistry Greenville, South Carolina

Furman International Study University of Munich 1989

Munich, Germany

C. PROFESSIONAL CREDENTIALS

1. Licensure

South Carolina #8554 1994 - Present

Colorado # 15337 1998 - Present

2. Board Certifications

Board Certification in Pharmacotherapy (BCPS) December 2000-December 2007

BCPS, Recertified January 2008- December 2014

BCPS, Added Qualifications in Cardiology March 2004-December 2011

AQ Cardiology, Recertified January 2012- December 2018

Certification in Geriatric Pharmacy (CGP) December 2005-December 2010

CGP, Recertified January 2011-December 2016

3. Other Certifications

Basic Life Support (BLS) 1998 – Present

Advanced Cardiac Life Support (ACLS) 1998-Present

4. Elected Fellowships

Fellow, American Society of Consultant Pharmacists 2005-Present

Fellow, Society of Geriatric Cardiology 2007-2009

Fellow, American College of Clinical Pharmacy 2007-Present

Fellow, American Heart Association- Council of Clinical Cardiology 2007- Present

Fellow, American Society of Health Systems Pharmacists 2009-Present

5. Institutional Credentialing

Internal Medicine University of Colorado Hospital 1999 – Present

Department of Pharmacy

Pediatrics University of Colorado Hospital 1999 – Present


Nutrition Support University of Colorado Hospital 1999 – Present


Investigational Drugs University of Colorado Hospital 1999 – Present


Drug Information University of Colorado Hospital 1999 – Present


Oncology University of Colorado Hospital 1999 – Present


D. PROFESSIONAL EXPERIENCE

Clinical Lead, Colorado Medicaid Drug Utilization Review Program. July 1, 2012-Present

Colorado Department of Health Policy and Finance.

University of Colorado School of Pharmacy

Denver, Colorado

Clinical Specialist, Division of Cardiology August 2000 – Present

Section of Advanced Heart Failure/Heart Transplant

Section of General Cardiology

University of Colorado Hospital

Denver, Colorado

Clinical Specialist, Department of Internal Medicine August 1998 -July 2000


Denver, Colorado

Interim Director, Pharmacy Practice Residency October 2002-Febuary 2003


Denver, Colorado

Community Pharmacist July 1994 – July 1998

Family Medicine Pharmacy

MUSC Family Medicine Center


Community Pharmacist July 1994-July 1998

Winn Dixie Pharmacy


E. ACADEMIC APPOINTMENTS

Associate Professor

Department of Physical Medicine & Rehabilitation August 2005-Present

University of Colorado

School of Medicine

Associate Professor

Department of Clinical Pharmacy July 2005-Present

University of Colorado

Skaggs School of Pharmacy and Pharmaceutical Sciences

Affiliate Faculty July 2004-July 2006

Department of Physical therapy

Regis University

Assistant Professor August 1998 – June 2005

Department of Pharmacy Practice

University of Colorado Health Sciences Center

Skaggs School of Pharmacy

F. GRANT/RESEARCH ACTIVITY

1. Funded Grants (Active and Completed)

Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina

and Diabetes: Impact on Cardiac Interventions, Healthcare Resource Utilization and Expenditures.

Gilead. Co-investigator (role: assisted with concept and protocol development). 10% salary offset,

5% effort. $158,754. July 2013-July 2014. On-going.

Estimating the Burden of Illness for Employees and Their Dependents with Acute Coronary

Syndrome and Diabetes (role: assisted with protocol development, sub-study development, abstract

preparation and presentation, manuscript preparation. Janssen.

0% salary offset, 2% effort. $45,635. April 2012-July 2013. Completed.

12% salary offset, 12% effort. $45,635. July 2013-July 2014. Completed.

Sedative Hypnotic Use by the Mentally Ill: A Medicaid Prescription Policy. National Institutes of

Health (5R01-MH086310). Co-investigator (role: assisted with sub-study development and

manuscript preparation). 20% salary offset, 10% effort. $273,804. June 2012-May 2013. Completed.

Pharmacogenomics of Calcineurin Nephrotoxicity in Cardiac Transplantation. American Heart

Association- PMA Fall 09, Pacific Mountain Affiliate. Co-investigator (assisted with protocol

development, patient enrollment, data collection and analysis). 0% salary offset. 2% effort.

$127,272. July 2012-June 2014. On-going.

Colorado Drug Utilization Review Program. Colorado Department of Health Policy and Financing.

Principal Investigator-Clinical Lead (role: assist with development of retro-DUR, prospective DUR,

clinical module development).

20% salary offset, 30% effort. $141,277. July 2011- June 2012. Completed.

30% salary offset. 35% effort. $141,277. July 2012- June 2013. Completed.

40% salary offset, 35% effort; $157,447. July 2013-June 2014. On-going.

Clinical Pharmacology Of Aliskiren In Combination With Cyclosporine In Cardiac Transplantation.

Co-investigator (role: assisted with protocol development, patient enrollment, data collection and

analysis). 0% salary offset. 2% effort. $120,000. July 2010-June 2012. Completed.

The Pharmacogenetics of Inhibitory Drug-Drug Interactions in Cardiac Transplantation. American

Heart Association, Pacific Mountain Affiliate. Co-investigator (role: assisted with protocol

development and data collection and analysis). 0% salary offset. 2.5% effort.$120,000. January

2007- December 2008. Completed.

Physical Therapists Knowledge, Practice and Attitudes towards Oral Non-steroidal Anti-

inflammatory Drugs (NSAIDs), Analgesics, and Nutritional Supplements/ Herbal Medicine.

American Physical Therapy Association-Colorado Chapter. Co-investigator (role: assisted with

protocol development, data analysis, data collection, and manuscript/abstract preparation). 0% salary

offset. 5% effort.$10,000. July 2003-July 2004. Completed.

The Relationship Between Melatonin and Tumor Necrosis Factor-alpha in Older Adults with

Involuntary Weight Loss. American Association of Colleges of Pharmacy New Investigators Grant.

Principal Investigator (role: conceived idea, wrote and submitted protocol, conducted data collection

and data analysis.). 0% salary offset. $5,000. 10% effort. December 2002-January 2005. Completed.

Optimization of Pharmacotherapy in Medically Acute Elderly Patients –the OPTIMAL Study.

University of Colorado Hospital. Principal Investigator (role: conceived idea, wrote and submitted

protocol, conducted all data collection and data analysis). $21,000. Principal Investigator. Funded.

0% salary offset. 10% effort. August 1999 – February 2003. Completed.

2. Unfunded Submitted Grants

Pharmacogenomic predicators of mycophenolate-induced hematologic toxicities in cardiac

transplantation. Skaggs Scholars Program. Co-investigator. $200,000. June 2013.

Impact of Left Ventricular Assist Devices on Plasma Protein Structure: A Translational Approach.

International Society of Heart and Lung Transplantation Grant. $12,000. Co-investigator. May 2013.

Clinical Pharmacology of Aliskiren in Cardiac Transplantation. NIH/NHLBI, R34 Clinical Trial

Pilot Study. Co-investigator. $450,000. December 2011.

WhicH Factors ImpaCt Hospital Readmission in Patients with Heart Failure-

WHICH-HF Patient-Centered Study. Principal Investigator. $23,000. University of Colorado Center

for Patient Safety. December 2010.

Investigation of the Pharmacokinetic interaction between Sirolimus and Simvastatin in Cardiac

Transplantation. American Heart Association. Co-investigator. $198,000. January 2009.

Improving Heart Failure Care and Outcomes in Nursing Home Residents. NIH (1 R01 AG033539-

01). Co-investigator. 10% effort. $100,000. June 2008.

Pharmacokinetics, Efficacy, And Safety Of Low-Dose Aliskiren In Combination With Cyclosporine

or Tacrolimus In Cardiac Transplantation. Novartis Pharmaceuticals. Co-investigator. $197,000. July

2008.

Absorption of Oral Vitamin B12 with Omeprazole-Induced Gastric Acid Suppression. University of

Colorado Center for Human Nutrition. Co-investigator. $44,663.November 2002.

Randomized, Double-Blind, Placebo Control Trial Evaluating Sertraline in Depressed Heart Failure

Patients- the BLUES II Study. Pfizer Pharmaceuticals. Co-investigator. $196,000. January 2001.

Enhancing Patient and Physician Compliance with Beta Blocker Therapy in Heart Failure. Glaxo-Smith

Kline Quality Care Research. Co-investigator. $200,825. July 2001.

Gender-based Access to Care for Heart Failure (the GRACE Study). AHRQ Research Grant

Program. Co-investigator. $98,002. July 2001.

Randomized, Double-Blind, Placebo Control Trial Evaluating Paroxetine in Depressed Heart Failure

Patients- the BLUES Study. SmithKline Beecham. Co-Investigator. $183,660. February 2000.

The Development and Implementation of a Pharmacist-Run Carvedilol Clinic in a Geriatric

Medicine Population. SmithKline Beecham. Principal investigator. $7,621. March 1999-2000.

A Comparison of Pharmacy Intervention Strategies in Model Ambulatory Care Settings for

Hypertensive Patients. Novartis/ University of Utah: Pharmaceutical Care/Disease Management

Outcomes Grant. Principal Investigator. $25,000. August 1998.

3. Unfunded Investigator Initiated (Active and Completed)

Impact of Left Ventricular Assist Devices on Plasma Protein Structure. Co-investigator. 2013-

Present. On-going.

Assessment of Medication Regimen Complexity in Heart Transplantation. Co-investigator. 2013-

Present. On-going.

Impact of Day, Month, and Hour of Admission on Inpatient Outcomes in Hospitalizations For

Congestive Heart Failure. Co-investigator. 2013-Present. Completed.

Heart and Lung Transplant Center Policies on Recreational and Medical Marijuana Use. Principal

Investigator. 2012-2013. Completed.

Evaluation of Low Dose Droperidol on QTc Prolongation in the Emergency Department. Co-

investigator 2012-Present. On-going

QT Prolongation Associated with Ondansetron in Patients with Underlying Cardiac Disease.

Principal Investigator. 2010-2011. Completed.

Impact of Renin-Angiotensin System Blockade on Proteinuria in Heart Transplant Recipients: An

Observational, Longitudinal Analysis. Principal Investigator. 2012-2013. Completed.

Integrated Telehealth and Care Management Program on All Cause Mortality in Medicare

Beneficiaries With Heart Failure. Co-investigator. 2012-2013. Completed.

Burden of Comorbidities and Medication Complexity in Heart Failure Patients Over A Single

Decade. Principal Investigator. 2012-2013. Completed.

Heart failure as a major cause of prolonged wound healing and increased healthcare cost in older

adults with chronic wounds. Principal Investigator. 2012-2013. Completed.

Effect of a City-Wide Smoking Ban on Maternal Smoking Prevalence and Risk Of Preterm And

Low Birth Weight Births: The Colorado Experience. Principal Investigator. 2010. Completed.

Statin Therapy is Cost-Effective for Vascular Event Prevention in Adults with Elevated C-Reactive

Protein: Implications of JUPITER . Co-investigator. 2010. Completed.

Impact of Nitroprusside on Hospital Readmission in Acute Decompensated Heart Failure. Co-

investigator. 2009. Completed.

Effect of Race and Sex on Health Care Resource Utilization by Medicare Beneficiaries With Heart

Failure. Principal Investigator. 2008. Completed.

Evaluation of Number of Providers Seen by Medicare Beneficiaries with Heart Failure. Principal

Investigator. 2008. Completed.

The Magnitude of Health Care Resource Utilization By Medicare Beneficiaries With Heart Failure.

Principal Investigator. 2007. Completed.

The Risk of Adverse Drug Events and Hospital-Related Morbidity and Mortality Among Older

Adults With Potentially Inappropriate Medication Use. Co-investigator. 2006. Completed.

The Relationship of TNF-Alpha And Involuntary Weight Loss in Older Outpatients. Co-investigator.

2005. Completed.

Characteristics of Sulfa Allergy and Use of Potentially Cross-Reactive Medications amongst Adult

Inpatients. Co-Investigator. 2004. Completed.

G. PUBLICATIONS

1. Refereed Journals (‡ denotes corresponding author)

1. Page RL2, Ghushchyan V, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, Nair KV.

The hidden costs associated with venous thromboembolism: Impact of lost productivity on

employers and employees. Journal of Occupational and Environmental Medicine 2013

[accepted].

2. Lewis WR, Piccini JP, Tuakhia MP, Curtis AB, Fang M, Suter RE, Page RL2, Fonarow GC.

Get with the Guidelines AFIB: A novel quality improvement registry for hospitalized

patients with atrial fibrillation. Circulation Quality Outcomes 2013 [submitted and under

review].

3. Trinkley KE, Nikels M, Page RL2, Joy MS. Automating and estimating glomerular filtration

rate for dosing medications and staging chronic kidney disease. International Journal of

General Medicine 2013 [accepted].

4. Kao DP, Page RL2, Macaulay D, Birnbaum HG, Jarvis JL, Desai US, Lindenfeld JA.

Impact of an integrated telehealth and care management program on all-cause mortality and

healthcare utilization in patients with heart failure. Journal of the American College of

Cardiology-Heart Failure 2013 [under review at CMS].

5. Shakowski C, Page RL2, Fish DN, Stolpman N. The Colorado Aurora theatre shooting:

Lessons learned in the department of pharmacy from a single center prospective. American

Journal of Health Systems Pharmacy 2013 [in press].

6. Trinkley KE, Page RL2, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and

the risk for torsades de pointe: Essentials for clinicians. Current Medical Research &

Opinion 2013; 29(12): 1719-26.


Economic burden of acute coronary syndromes for employees and their dependents: Medical

and productivity costs. Journal of Occupational and Environmental Medicine 2013; 55(7):

761-767.

8. Laforest SK, Chow SL, DiDomenico RJ, Dracup K, Ensor C, Gattis-Stough W, Heywood J,

Lindenfeld JA, Page RL2, Patterson H, Vardeny O, Massie B. Clinical pharmacy services in

heart failure: White paper from the Heart Failure Society of America and American College

of Clinical Pharmacy Cardiology Practice and Research Network. Journal of Cardiac Failure

2013; 19(5): 354-69.

9. Laforest SK, Chow SL, DiDomenico RJ, Dracup K, Ensor C, Gattis-Stough W, Heywood J,

Lindenfeld JA, Page RL2, Patterson H, Vardeny O, Massie B. Clinical pharmacy services in

heart failure: White paper from the Heart Failure Society of America and American College

of Clinical Pharmacy Cardiology Practice and Research Network. Pharmacotherapy 2013;

33(5): 529-48.

10. Wiggins BS, DiDomenico RJ, Rodgers RE, Miller A, Page RL2. Discharge counseling in

heart failure and myocardial infarction – a best practices model. Pharmacotherapy 2013;

33(5): 558-80.

11. Golightly LK, Barber GR, Barron MA, Page RL2. Statins and daptomycin: Safety

Assessment of concurrent use and evaluation of drug interaction liability. Drug Metabolism

and Drug Interaction 2013; 28(1): 49-58.

12. Morrow DA, Fang JC, Fintel DJ, Granger CG, Katz JN, Kushner FG, Juvin JT, Lopez-

Sendon J, McAreavery D, Nallamothu B, Page RL 2, Parrillo JE, Peterson PN, Winkelman

C. AHA Scientific Statement: Evolution of critical care cardiology and the emerging need for

new staffing and training models. Circulation 2012; 126(11): 1408-1428.

13. Page RL2, Ghushchyan V, Allen R, Roper L, Beck D, Bamrom JH, Tomas, FF, Chan W,

McQueen B, Nair KV. The costs and outcomes associated with clopidogrel discontinuation

in Medicare beneficiaries with acute coronary syndrome in the coverage gap. Drugs,

Healthcare and Patient Safety 2012;4:67-74.

14. Page RL2, Lindenfeld JA. The comorbidity conundrum : A focus on the role of

noncardiovascular chronic conditions in the heart failure patient. Current Cardiology

Reports. 2012; 14: 276-84.‡

15. Page RL2, Slejko J, Libby A. A city-wide smoking ban reduced maternal smoking and risk

for preterm, not low birth weight, births: A Colorado natural experiment. Journal of

Women’s Health. 2012; 21(6): 621-7. ‡

16. Page RL2, Spruck P, Bainbridge JL, Michalek J, Quaife RA. Seizures associated with

regadenoson: A case series. Journal of Nuclear Cardiology. 2012; 19(2): 389-391. ‡

17. Page RL2, Luna M, Brieke A, Lindenfeld J. Low-dose gabapentin for resistant intractable

hiccups in a heart transplant recipient. Progress in Transplantation. 2011; 21: 340-343.‡

18. Hafferman JM, Namdar R, Seibold GE, Page RL2. The effect of intravenous ondansetron on

QT interval prolongation in patients with cardiovascular disease and additional risk factors

for Torsades: A prospective, observational Study. Drugs, Healthcare and Patient Safety.

2011:3: 53-58. ‡

19. Page RL2, Ghuschchyan V, Nair K. A call to action: Responding to the future forecasting of

cardiovascular disease in America. American Health & Drug Benefits.2011:4(5): 280-288.

20. Rohrer C, Page RL2, Shakar S, Lindenfeld J. Carvedilol for the treatment of BPH in patients

with heart failure? Journal of Cardiac Failure. 2011; 17(10): 875-77.

21. Holmes DR, Becker JA, Granger CB, Limacher MC, Page RL2, Sila C. ACCF/AHA 2011

health policy statement on therapeutic interchange and substitution. Journal of the American

College of Cardiology 2011; 58(12): 1287-1307.

22. Holmes DR, Becker JA, Granger CB, Limacher MC, Page RL2, Sila C. ACCF/AHA 2011

health policy statement on therapeutic interchange and substitution. Circulation 2011; 124:

1290-1310.

23. Page RL2, Mueller S, Levi M, Lindenfeld J. Pharmacokinetic drug-drug interactions

between immunosuppressant and anti-infective agents: Implications for therapeutic drug

monitoring. Journal of Heart and Lung Transplant. 2011; 30(2): 124-135.‡

24. Slejiko JF, Page RL2, Sullivan P. Cost-effectiveness of statin therapy for vascular event

prevention in adults with elevated C-reactive protein: Implications from JUPITER. Current

Medical Research and Opinion 2010; 26(10):2485-97.

25. Page RL2, Linnebur SA, Bryant LL, Ruscin JM. Inappropriate prescribing in the

hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.

Clinical Interventions in Aging 2010;5:75-87. ‡

26. Chow SL, Dorsch M, Dunn S, Jackevicius C, Page RL2, Trujillo T, Vardeny O, Wiggins B,

Bleske BE. Key articles related to complementary and alternative medicine in cardiovascular

disease. Pharmacotherapy 2010 30(1):1e–49e. Available at

http://www.accp.com/docs/prns/card/Pharm3001e_Chow-CAM-KA.pdf.

27. Linnebur SA, Vande Griend JP, Dugan JP, Page RL2. Positive Beers Criteria: Limitations

(letter). Consultant Pharmcist 2009;24(11)783.

28. Page RL2, Hume AL, Trujillo JM, Leader G, Vardeny O, Neuhauser M, Dang D, Nesbit S,

Cohen LJ. Interprofessional education: Principles and application-A framework for clinical

pharmacy. Pharmacotherapy 2009; 29(7): 145e-164e. Available at

http://www.accp.com/docs/positions/whitePapers/InterProfEduc.pdf

29. Jackevicuius CA, Page RL2, Chow S, Dunn S, Lee CR, Ng TM, Rodgers JE, Vardeny O,

Wiggins BS, Munger MA. High-impact articles related to management of heart failure: 2008

update. Pharmacotherapy 2009; 29 (1): 82-112.

30. Bainbridge JL, Page RL2, Ruscin MJ. Elucidating the mechanism of action and potential

interactions of MAO-B inhibitors. Neurologic Clinics. 2008; 26: S85-96.

31. Page RL2, Cantu M, Lindenfeld J, Hergott L, Lowes B. Possible Heart Failure Exacerbation

Associated With Pregabalin: Case Discussion and Literature Review. Journal of

Cardiovascular Medicine (Italian Heart Journal). 2008; 9(9):922-5. ‡

32. Page RL2, Nair K, Barton P. Effect of cost-sharing for prescription medications on health

outcomes in older adults: A critical review of the literature and potential implications for

managed care. Consultant Pharmacist. 2008; 23: 37-54. ‡

34. Owens P, Garner J, Hergott L, Page RL2. Clopidogrel desensitization: Patient case and review

of published protocols. Pharmacotherapy 2008; 28: 259-270. ‡

35. Page RL2, Ruscin JM, Bainbridge JL, Brieke A. Restless legs syndrome induced by

escitalopram: Case discussion and literature review. Pharmacotherapy 2008; 28:271-

280. ‡

36. Page RL2, Ferguson D, Cantu M. An Alternative Salvage Regimen for Helicobacter Pylori

Resistant Patients with Heart Failure. Cardiology 2008; 110: 112-5. ‡

37. Page RL2, Utz K, Wolfel G. Should β-blockers be used in the treatment of cocaine associated

acute coronary syndrome? Annals of Pharmacotherapy 2007; 41: 2008-13. ‡

38. Turner CJ, Ellis S, Giles J, Maffeo C, Hansen L, Saseen JJ, Ulrich H, Valdez C, Altiere R,

Bainbridge J, Page RL2, Sintek C, Vondracek S, Zadvorny E, Fish D. A strategy to develop

advanced pharmacy practice experiences. American Journal of Pharmaceutical Education

2007; 71(3): 46-49.

39. Page RL2, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with

disseminated zygomycosis-case discussion and literature review. Pharmacotherapy 2007;

27(2): 290-98. ‡

40. Page RL2, Ruscin JM. The risk of adverse drug events and hospital-related morbidity and

mortality among older adults with potentially inappropriate medication use. American

Journal of Geriatric Pharmacotherapy. 2006; 4(4): 297-305.

41. Ruscin JM, Page RL2, Scott S. Probable hydrochlorothiazide-induced angioedema in a

sulfonamide-antibiotic allergic patient. American Journal of Geriatric Pharmacotherapy

2006; 4(4): 325-329. ‡

42. Page RL2, Smith M, Scherer S. Evaluation of physical therapists’ knowledge, attitudes, and

professional use of dietary supplements: Implications for practice and education.

Journal of Allied Health 2006; 35(4): 298E-315E. ‡

43. Saseen JJ, Grady SE, Hansen LB, Hodges BM, Kovacs SJ, Martinez LD, Murphy JE, Page

RL2, Reichert MG, Stringer KA, Taylor CT. Future clinical pharmacy practitioners should

be board-certified specialists. Pharmacotherapy 2006; 26(12): 1816-25.

44. Page RL2, Bainbridge, JL. Intractable epistaxis associated with topiramate administration.

Annals of Pharmacotherapy 2006; 40 (7/8):1462-1465. ‡

45. Turner CJ, Altiere R, Fish D, Giles J, Page RL2, Sintek C, Ulrich H, Valdez C, Vondracek

S, Zadvorny E. Mapping CAPE outcomes in an advanced pharmacy practice experiential

program: A description and evaluation of an assessment system. American Journal of

Pharmaceutical Education 2006; 70(3): 60-68.

46. Hemstreet B, Page RL2. Sulfonamide allergies and outcomes related to use of potentially

cross-reactive drugs in hospitalized patients. Pharmacotherapy 2006; 26(4): 551-557.

47. Juang P, Page RL2, Zolty R. Probable loop diuretic-induced pancreatitis in a sulfonamide-

allergic patient. Annals of Pharmacotherapy 2006; 40(1):128-34. ‡

48. Juang P, Page RL2, Zolty R. A successful rapid desensitization protocol in a loop diuretic

allergic patient. Journal of Cardiac Failure 2005; 11(6): 481. ‡

49. Page RL2, Klem P, Rogers C. Potential elevation of tacrolimus trough concentrations with

concomitant metronidazole therapy. Annals of Pharmacotherapy 2005; 39(6):1109-

13. ‡

50. Page RL2, Smith M, Scherer S. Evaluation of physical therapists' knowledge, attitudes, and

professional use of oral over the counter analgesic medications: A potential impact for

pharmacists. American Journal of Health Systems Pharmacists 2005; 62(14):1440-1. ‡

51. Ruscin JM, Page RL2, Yeager B, Wallace J. The relationship of TNF-alpha and involuntary

weight loss in older outpatients. Pharmacotherapy 2005; 25(3): 313-19.

52. Page RL2, Lindenfeld JA, Miller GG. Drug therapy in the heart transplant recipient. Part 4:

Drug Interactions. Circulation 2005; 111(2): 238-248.

53. Lindenfeld JA, Page RL2, Zolty R, Shakar SF, Levi M, Lowes B, Wolfel EE, Miller, GG.

Drug therapy in the heart transplant recipient. Part 3: Common Medical Problems.

Circulation 2005; 111(1): 113 - 117.

54. Lindenfeld JA, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni LE,

Page RL2, Kobashigawa J. Drug therapy in the heart transplant recipient. Part 2:

Immunosuppressive Drugs. Circulation 2004; 110(25): 3858 – 3865.

55. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni LE,

Page RL2, Kobashigawa J. Drug therapy in the heart transplant recipient. Part 1: Cardiac

rejection and immunosuppressive Drugs. Circulation 2004; 110 (24): 3734 - 3740.

56. Page RL2, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with

rosiglitazone: Case discussion and literature review. Pharmacotherapy 2003; 23(7): 945-54. ‡

57. Ruscin JM, Page RL2. Inappropriate prescribing for elderly patients. (letter). Journal of the

American Medical Association 2002; 287(10):1264-5.

58. Ruscin JM, Page RL2, Valuck RJ. Vitamin B12 deficiency following extended use of

histamine 2 blockers and a proton pump inhibitor. Annals of Pharmacotherapy. 2002; 36(5):

812-816.

59. Page RL2, Ruscin JM, Fish D. LaPointe M. Possible interaction between azithromycin and

cyclosporine. Pharmacotherapy 2001; 21(11): 1436-1443. ‡

60. Ruscin JM, Page RL2. Newer pharmacologic agents and their relevance to older adults.

Annals of Long-Term Care 2001; 9 (10): 43-55.

61. Page RL2, Lawrence JD. Warfarin potentiation by dong quai. Pharmacotherapy 1999;

19(7): 870-76.

62. Page RL2, O’Neil MG, Yarbrough DB, Conradi S. A fatal case of toxic epidermal

necrolysis related to lamotrigine administration. Pharmacotherapy 1998; 18 (2): 392-8.

63. Page RL2, Jones KW, Jebaily GC. Can women live on bread alone? Folic acid

supplementation revisited. Journal - South Carolina Medical Association 1997; 93 (2): 53-

2. Non-refereed Journals

1. Page RL2. The drug shortage conundrum: A call to action. Cardiology-ACC in Touch.

Summer 2013. ‡

2. Page RL2. Delineating potential roles for pharmacists in the management of acute coronary

syndromes. Pharmacy Practice News. February 2011. ‡

3. Lenoir GJ, Page RL2. Inpatient treatment of acute coronary syndromes: Pharmacological

implications. APhA Special Report, Pharmacy Today Supplement. October 2010. ‡

4. Page RL2. Rhythm control in atrial fibrillation: mapping current and emergent therapies.

Pharmacy Times. August 2009. ‡

5. Page RL2. Women with hypertension face unique challenges. Pharmacy Times. February

2009.

6. Page RL2. Women with hypertension: Still a battle of the sexes? Pharmacy Times.

December 2008. **, ‡

7. Page RL2. Reviewing the complexities of morning hypertension. Pharmacy Times.

December 2008. **, ‡

8. Page RL2. Osteoarthritis: Reviewing current standards of care and new therapeutic insights.

Pharmacy Times. November 2008. ‡

9. Page RL2. Women with diabetes and hypertension: A true “femme fatale”. Pharmacy Times.

November 2008. ‡

10. Page RL2. Morning hypertension and diabetes: A powerful predictor for future

complications. Pharmacy Times. November 2008. ‡

11. Page RL2. Hypertension in pregnancy: An emerging risk for cardiovascular disease.

Pharmacy Times. October 2008. ‡

12. Page RL2. Morning blood pressure and cardiovascular events: A deadly association.

Pharmacy Times. October 2008. ‡

13. Page RL2. Home Is where the heart is. New guidelines recommend home blood-pressure

monitoring. Pharmacy Times. September 2008. ‡

14. Page RL2. Preecalmpsia, blood pressure, and maternal outcomes: The potential role for

home blood-pressure monitoring. Pharmacy Times. September 2008. ‡

15. Page RL2. Emergent Management of Ischemic Stroke: Treatment ABCs. Pharmacy Times.

August 2008. ‡

16. Page RL2. Chronic Kidney Disease: Care Across the Continuum. Pharmacy Times. April

2008. ‡

17. Page RL2. Home Blood Pressure Monitoring: A Call to Action for Pharmacists. Pharmacist

to Pharmacist Education. Pharmacy Times. December 2007. ‡

18. Lewis V, Page RL2. High Blood Pressure: Getting the Most Out of Home Monitoring.

Pharmacist to Patient Education. Pharmacy Times. October 2007. ‡

19. Page RL2. Early to Rise: Morning Surge Hypertension and Implications for Home Blood

Pressure Monitoring. Pharmacy Times. June 2007. ‡

20. Gibson K, Page RL2. What’s UP with Morning Hypertension. Pharmacist to Pharmacist

Education. Pharmacy Times. April 2007. ‡

21. Gibson K, Page RL2. Early to Rise? Your Blood Pressure May Be Too! Pharmacist to

Patient Education. Pharmacy Times. April 2007. , ‡

22. Imel G, Page RL2. Putting acetaminophen poisoning into perspective. Pharmacy Times.

March 2006. **, ‡

23. Owens PS, Page RL2. Does recombinant tissue plasminogen activator have a role in acute

ischemic stroke? Pharmacy Times. December 2005. ‡

24. Page RL2. Evaluating the benefits of low dose aspirin. Pharmacy Times. October 2005., ‡

25. PageRL2. High blood pressure and angina: Tuning in to your body’s rhythms. Pharmacy

Times. April 2005. ‡

26. PageRL2. Evolving concepts in chronotherapy with CCBs: Implications for pharmacists.

Pharmacy Times. April 2005. ‡

27. Page RL2. ARBs: their role in stroke prevention and cognitive improvement. Cardiology

Today. February 2005. ‡

28. Page RL2. Ciprofloxacin-cyclosporine interaction: Fact or fantasy? Infectious Disease

News. June 2004. ‡

29. Page RL2. Immunosuppressant drug interactions with newer antifungals. Infectious Disease

News. June 2004. ‡

30. Page RL2. Does aspirin resistance in CVD actually exist? Cardiology Today. April 2004. ‡

31. Ruscin JM, Page RL2. The pros and cons of mixing meds with endurance sports. Trail

Runner Magazine. December/January 2001-2002.

32. Page RL2. Hospital pharmacy: More than just a career in the basement. Pharmacy Times,

Fall 2001 Supplement.

33. Page RL2. Lipodystrophy associated with protease inhibitors. Infectious Disease News

1999; 12 (8): 38-41. ‡

34. Page RL2. Hyperglycemia associated with protease inhibitors. Infectious Disease News

1999; 12 (7): 39-40. ‡

35. Page RL2. Tramadol: a painfully expensive alternative. Primary Care Therapeutics 1996;

2(1): 16-23. ‡

3. Book Chapters

1. Trinkley K. Page RL2. Medication Safety Issues in Cardiology. In: Murphy J, Lee M, eds.

Pharmacotherapy Self-Assessment Program, 8th edition. Kansas City, MO: American

College of Clinical Pharmacy. January 2013.

2. Aquilante C, Page RL2. Chapter 11-Cardiovascular Pharmacogenomics. In: Bertino J, Ma

JD, Kashuba A, Fuhr U, DeVane CL, editors. Textbook of Pharmacogenomics: an

Introduction and Clinical Perspective. New York: McGraw Hill. 2012.

3. Page RL2, Ruscin JM. Inappropriate Prescribing in the Hospitalized Elderly Patient. In:

Wehling M, editor. Drug Therapy in the Elderly. New York, Springer. 2012.

4. Wehling M, Page RL2. Heart Failure. In: Wehling M, editor. Drug Therapy in the Elderly.

New York, Springer. 2012.

5. Page RL2. Cardiology III. In: Updates in Therapeutics: The Pharmacotherapy Preparatory

Course, 2012 Edition. Lenexa: American College of Clinical Pharmacy. Lenexa, KS. 2012.

6. Page RL2, Nappi JM. Chapter 18. Acute Coronary Syndromes. In: Koda-Kimble MA,

Young LY, editors. Applied Therapeutics: The Clinical Use of Drugs. 10th ed. Philadelphia:

Lippincott Williams & Wilkins. 2012.

7. Page RL2, Murphy JE. Chapter 19: Procainamide. In: Murphy JE, ed. Clinical

Pharmacokinetics, 5th edition. Bethesda, MD: American Society of Health Systems

Pharmacists. 2011.

8. Page RL2. Chapter 12: Digoxin. In: Murphy JE, ed. Clinical Pharmacokinetics, 5th edition.

Bethesda, MD: American Society of Health Systems Pharmacists. 2011.

9. Page RL2. Cardiology III. In: Updates in Therapeutics: The Pharmacotherapy Preparatory

Course, 2011 Edition. Lenexa: American College of Clinical Pharmacy. Lenexa, KS. 2011.

10. Nappi JM. Page RL2. Chapter 18. Diastolic Heart Failure and the Cardiomyopathies. In:

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy:

A Pathophysiological Approach, 8th edition. New York, NY: McGraw-Hill, 2011.

11. Page RL2. Outpatient Cardiology. In: Updates in Therapeutics: The Pharmacotherapy

Preparatory Course, 2010 Edition. Lenexa: American College of Clinical Pharmacy. Lenexa,

KS. 2010.

12. Page RL2, Nappi JM. Drug-Induced Hypotension. In: Tisdale J, editor. Drug-Induced

Diseases: Prevention, Detection and Management, 2nd ed. Besethda: American Society of

Health Systems Pharmacists. Bethesda, MD. 2010.

13. Page RL2. Chapter 8. Heart Transplantation. In: Crouch MA, editor. Cardiovascular

Pharmacotherapy: A Point-of-care Guide. 1st edition. Bethesda, MD: American Society of

Health Systems Pharmacists. 2010.

14. Kim MS, Page RL2, Casserly I. Chapter 10: Synthetic Factor Xa Inhibition in Acute

Coronary Syndromes. In: Askari, AT, Lincoff, AM, editors. 1st ed. New York: Springer

Humana Press. Antithrombotic Drug Therapy in Cardiovascular Disease. 2009.

15. Page RL2, Spencer AP. Outpatient Cardiology. In: Updates in Therapeutics: The

Pharmacotherapy Preparatory Course, 2009 Edition. Lenexa: American College of Clinical

Pharmacy. Lenexa, KS. 2009.

16. Page RL2, Nappi JM. Chapter 18. Myocardial Infarction. In: Koda-Kimble MA, Young LY,

editors. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Philadelphia: Lippincott

Williams & Wilkins. 2008.

17. Nappi JM. Page RL2. Chapter 18. Diastolic Heart Failure and the Cardiomyopathies. In:

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy:

A Pathophysiological Approach, 7th edition. New York, NY: McGraw-Hill, 2008.

18. Page RL2, Murphy JE. Chapter 15: Procainamide. In: Murphy JE, ed. Clinical

Pharmacokinetics, 4th edition. Bethesda, MD: American Society of Health Systems

Pharmacists. 2008.

19. Job ML, Page RL2. Chapter 9: Digoxin. In: Murphy JE, ed. Clinical Pharmacokinetics, 4th

edition. Bethesda, MD: American Society of Health Systems Pharmacists. 2008.

20. Page RL2. Cardiac Transplantation. In: Schumock G, Brundage D, Chapman M, et al, eds.

Pharmacotherapy Self-Assessment Program, 6th edition. Kansas City, MO: American

College of Clinical Pharmacy. January 2007.

21. Nappi JM, Page RL2. Chapter 18. Myocardial Infarction. In: Koda-Kimble MA, Young LY,

editors. Applied Therapeutics: The Clinical Use of Drugs. 8th ed. Philadelphia: Lippincott

Williams & Wilkins. 2005.

22. Page RL2, Nappi JM. Drug-Induced Hypotension. In: Tisdale J, editor. Drug-Induced

Diseases: Prevention, Detection and Management, 1st ed. Bethesda: American Society of

Health Systems Pharmacists. Bethesda, MD. 2005.

4. Published and Presented Abstracts

1. Page RL2, Ghushchyan V, Hoetzer G, Bhandary D, Van Den Bos J, Grey T, Norris DT, Nair

KV. Death is expensive: Evaluation of inpatient mortality for acute coronary syndrome

admission. American Heart Association-QCOR Scientific Sessions. Baltimore, MD, June

2014.

2. Page RL2, Ghushchyan V, Allen RR, Hartsfield C, Koch BR, Nair KV. Ranolazine

improves cardiovascular outcomes and healthcare utilization: A comparative effective

analysis with traditional antianginal agents. American Heart Association-QCOR Scientific

Sessions. Baltimore, MD, June 2014.

3. Foley TR, Page RL2, Lutrell T, Lindenfeld JA. The spectrum of chronic wounds in older

adults with heart failure. American College of Cardiology Scientific Sessions. Washington,

DC. March 2014.


Atrial fibrillation and heart failure increase length of hospital stay, total healthcare utilization,

and costs of acute coronary syndrome. American Heart Association Scientific Sessions.

Dallas, TX. November 2013.

5. Kao DP, McIlvennan C, Page RL2, Lindenfeld JA. Impact of day, month, and hour of

admission on inpatient outcomes in 949,907 hospitalizations for congestive heart failure.

European Society of Cardiology-Heart Failure Congress. Lisbon, Portugal. May 2013.

6. Ghushchyan V, Page RL2, Gifford B, Allen RR, Raut M, Crivera C, Naim, AB, Nair KV.

Economic burden of acute coronary syndrome: health care and productivity costs.

International Society of Pharmaceutical Outcomes and Research. New Orleans, LA. May

2013.

7. Page RL2, Keller K, Ambardekar AV, Lindenfeld JA. Heart and lung transplant center

policies on recreational and medical marijuana use. American Heart Association-QCOR

Scientific Sessions. Baltimore, MD. May 2013.


Economic Burden of Deep Vein Thrombosis and Pulmonary Embolism for Employees and

Employers American Heart Association-QCOR Scientific Sessions. Baltimore, MD. May

2013.

9. Shakowski C, Page RL2, Shakar S, Brieke A, Wolfel EE, Allen L, Ambardekar A,

Lindenfeld. Renin-angiotensin system blockade reduces proteinuria in heart transplant

recipients: an observational, longitudinal analysis. International Society of Heart and Lung

Transplantation. Montreal, Canada. April 2013.

10. Aquilante C, Page RL2, Brieke A, Hopley CW, Christians U, Hoffman KL, Schniedewind

B. SLCO1B1 genotype influences the drug-drug interaction between cyclosporine and

pravastatin. International Society of Heart and Lung Transplantation. Montreal, Canada.

April 2013.

11. Aquilante C, Page RL2, Vu A, Roscoe N, Wolfel EE, Lindenfeld JA. Office and home

systolic blood pressures are underestimated in heart transplant recipients. International

Society of Heart and Lung Transplantation. Montreal, Canada. April 2013.

12. Ross JL, Kiser TH, Page RL2. Serum thiocyanate levels in critically ill patients receiving

sodium nitroprusside infusions. American Society of Health System Pharmacists Clinical

Midyear Meeting. Las Vegas, NV. December 2013.

13. Page RL2, Kao DP, Macaulay D, Birnbaum HG, Jarvis J, Desai U, Lindenfeld JA.

Integrated telehealth and care management program reduces all cause mortality in Medicare

beneficiaries with heart failure. American Heart Association Scientific Sessions. Los

Angeles, CA. November 2012.


Economic burden of acute coronary syndromes for employees and their dependents: Medical

and productivity costs. American Heart Association Scientific Sessions. Los Angeles, CA.

November 2012.

15. Shipp K, Page RL2, Keller K, Lindenfeld JA. Evaluation of the Use and Policies for

Medical Marijuana in Heart and Lung Transplant Recipients: A Survey of United States

Transplant Medical Directors. American College of Clinical Pharmacy Fall Meeting.

Hollywood, FL. October 2012.

16. Page RL2, Lindenfeld JA, Allen R, Nair KV. Burden of comorbidities and medication

complexity in heart failure patients significantly increases over a single decade. European

Society of Cardiology-Heart Failure Congress. Belgrade, Serbia. May 2012.

17. Page RL2, Lutrell T, Lindenfeld JA. Heart failure as a major cause of prolonged wound

healing and increased healthcare cost in older adults with chronic wounds. European Society

of Cardiology-Heart Failure Congress. Belgrade, Serbia. May 2012.

18. Page RL2, Slejko JF, Libby A. Effect of a city-wide smoking ban on maternal smoking

prevalence and risk of preterm and low birth weight births: The Colorado experience.

American Public Health Association Scientific Sessions. Denver, CO. November 2010.

19. Slejko JF, Page RL2, Sullivan P. Statin Therapy is Cost-Effective for Vascular Event

Prevention in Adults with Elevated C-Reactive Protein: Implications of JUPITER . American

College of Cardiology Annual Scientific Sessions. Atlanta, GA. March 2010.

20. Howard J, Nordon-Craft Amy, Page RL2, Struessel Tami. The importance of adverse drug

event identification by the physical therapist in the acute neurological rehabilitation setting

to optimize patient outcome: A case example. American Physical Therapy Association

Combined Secessions. San Diego, CA. February 2010.

21. Slejko JF, Page RL2, Sullivan P. Cost-Effectiveness Of Statin Therapy For CHD prevention

in adults with elevated c-reactive protein: Implications of JUPITER. Annual Meeting of the

Society for Medical Decision Making. Hollywood, CA. October 2009.

22. Spencer AP, Page RL2. Decreased hospital readmission with nitroprusside in acute

decompensated heart failure. Heart Failure Society of America Scientific Secessions. Boston,

MA. September 2009.

23. Page RL2, Hogan C, Strongin K, Mills R, Lindenfeld J. Sex and race dictate health care

resource utilization by Medicare beneficiaries with heart failure. American Heart Association

Scientific Sessions. New Orleans, LA. November 2008.

24. Page RL2, Hogan C, Strongin K, Mills R, Lindenfeld J. Medicare beneficiaries with mild to

severe heart failure see 15-23 different providers annually. American Heart Association

Scientific Sessions. New Orleans, LA. November 2008.

25. Page RL2, Barton PL, Hogan C, Allen RR, Nair K. Utilization of health care resources by

medicare beneficiaries with heart failure stratified by a three-tier definition. AcademyHealth

Scientific Meeting. Washington, DC. June 2008.

26. Page RL2, Strongin K, Mills R, Lindenfeld J. The magnitude of health care resource

utilization by medicare beneficiaries with heart failure. American Heart Association

Scientific Sessions. Orlando, FL. November 2007.

27. Wells D, Flynn K, Page RL2, Spencer AP. Effect of amiodarone on argatroban dosing.

American College of Clinical Pharmacy Spring Meeting. Memphis, TN. April 2007.

28. Vogel N, Page RL2. Retrospective evaluation of omega-3 fatty acids in heart transplant

recipients. American Society of Health System Pharmacists Midyear Clinical Meeting.

Anaheim, CA. December 2006.

29. Conyers K, Page RL2, Watkins V, Godcharles S, Hergott L. Development &

implementation of a perioperative beta blocker protocol for noncardiac surgery. Cleveland

Clinic 2nd Annual Peri-operative Summit. Cleveland, OH. September 2006.

30. Page RL2, Scherer SA, Smith MA. Evaluation of physical therapist’s knowledge, attitudes,

and use of over the counter oral analgesics. American Society of Health System Pharmacists

Midyear Clinical Meeting. Orlando, FL. December 2004.

31. Hemstreet B, Page RL2. Characteristics of sulfa allergy and use of potentially cross-reactive

medications amongst adult inpatients. American College of Clinical Pharmacy Fall Meeting.

Dallas, TX. October 2004.

32. Sherer S, Smith M, Page RL2. Physical therapists knowledge, practice and attitudes towards

oral non-steroidal anti-inflammatory drugs, analgesics, and nutritional supplements/ herbal

medicine. American Physical Therapy Association. Colorado Springs, CO. April 2004.

33. Voss M, Ruscin C, Page RL2, Hart DL, Wolfel G, Reed J, Dolson S. University of Colorado

Hospital compliance with the american heart association standards for secondary prevention

of coronary artery disease. American Heart Association. Denver, CO. November 2003.

34. McCollum M, Page RL2, Nair K, Valuck RJ. Gender bias in the use of beta-blocker therapy

in heart failure patients: report from the GRACE Study. American College of Clinical

Pharmacy Spring Practice and Research Forum and Updates in Therapeutics. Palm Springs,

CA. April 2003.

35. Page RL2, Paulsen S, Nuzum D. Student Opinion of Effectiveness of a Longitudinal Versus

an Elective Herbal Course. American Association of Colleges of Pharmacy Fall Annual

Meeting. Minneapolis, MN. July 2003.

36. Follin SL, Hansen L, Page RL2. Evaluation of men’s knowledge and perceptions of

osteoporosis risk and lifestyle modifications. American College of Clinical Pharmacy Fall

Meeting. Albuquerque, NM. October 2002.

37. Page RL2, Thompson D, Paulsen S. Using "Wit" to introduce humanistic issues to first year

pharmacy students. American Association of Colleges of Pharmacy Annual Meeting. Kansas

City, MO. July 2002.

38. Page, RL2, Ruscin JM, Nair K. Evaluation and comparison of internist versus geriatrician

management of heart failure pharmacotherapy in university-based ambulatory clinics.

American Society of Health Systems Pharmacists Midyear Clinical Meeting. New Orleans,

LA. December 2001.

39. Page RL2, Saseen JJ, Follin SL, Hammer D. Implementation of an oral examination process

in a pharmacotherapy course series. American Association of Colleges of Pharmacy Annual

Meeting. Toronto, Canada. July 2001.

40. Sprik R, Page RL2, Ruscin JM. Comparison of internist versus cardiologist management of

heart failure in an university-based internal medicine clinic. American College of Clinical

Pharmacy Spring Meeting. Salt Lake, UT. April 2001.

41. Miller S, Page RL2, Hammer D, Jarvis C. Development and implementation of a

pharmacy career development program. American Society of Health Systems Pharmacists.

Clinical Midyear Meeting. Las Vegas, NV. December 2000.

42. Follin S, Page RL2. “Evaluation of patient perceptions of clinical pharmacy services in an

urban community pharmacy setting. American Society of Health Systems Pharmacists


43. Page RL2, Hammer D. Development of a faculty rotation with pharmacy practice residents.

American Association of Colleges of Pharmacy Annual Meeting. San Diego, CA. July 2000.

44. Sprik R, Page RL2. Comparison of internist versus cardiologist management of heart failure

in an university-based internal medicine clinic. Merck Undergraduate Research Conference.

Denver, CO. June, 2000.

45. Smith M, Thompson E, Knutson P, Maffeo C, Page RL2. Evaluation of the educational

quality of internship experiences at University Hospital. American Society of Health Systems

Pharmacists, Clinical Midyear Meeting. Las Vegas, NV. December 1999.

46. Barnette D, Page RL2. Implementation of an entry-level pharmacy student refill program in

a university-based internal medicine clinic. American Association of Colleges of Pharmacy

Annual Meeting. Boston, MA. July 1999.

47. Smith M, Thompson E, Knutson P, Maffeo C, Page RL2. Evaluation of the educational

quality of internship experiences at University Hospital. Merck Undergraduate Research

Conference. Denver, CO. June, 1999

48. Pollock S, Ruscin M, Bainbridge J, Page RL2. Concurrent use of cholinesterase inhibitors

and anticholinergic agents in patient’s with Alzheimer’s disease. American Colleges of

Clinical Pharmacy, International Pharmacy Congress. Paris, France. April 1999.

49. Lawrence JD, Page RL2, Lawrence DB. Identifying the cholesterol lowering needs and

documenting therapy results in an ambulatory population. American College of Clinical

Pharmacy Fall Meeting. Salt Lake, UT. October 1998.

50. Nappi JM, Page RL2, Keyes K. An integrated 24 month pharmacy

practice/pharmacotherapy residency. American Society of Health Systems Pharmacists

Midyear Clinical Meeting. Las Vegas, NV. December 1997.

5. Other Publications

1. Page RL2, Holmes DR. Slide Set for the ACCF/AHA 2011 Health Policy Statement on

Therapeutic Interchange and Substitution. Available at:

http://content.onlinejacc.org/cgi/content/full/j.jacc.2011.06.001/DC2

2. Page RL2. Heart Failure: Pharmacologic Management Update. Trinity Health Force

Learning. October 2005.

3. Page RL2, Ruscin JM. 2002 Update in Pain Management for Osteoarthritis and Rheumatoid

Arthritis. Continuing Education for the Northern California Chapter of the Arthritis

Foundation and Pharmacy Planning Services, Inc. November 2002.

4. Page RL2. Willow, Wintergreen, Witch Hazel, Wormwood, Woundwort, Yarrow. In:

Doyle RM, Harold C, Johnson P (eds). Nursing Herbal Medicine Handbook. First Edition.

Lipincott Williams & Wilkins, Springhouse Division. Springhouse, PA. 2001-2005.

5. Page RL2. Benzocaine, Activated Charcoal, Alpha-D-Galactosidase Enzyme, Kaolin &

Pectin, Lactase Enzyme, Malt Soup Extract, Sunscreens and Sunblocks. In: Doyle RM,

Harold C, Johnson P (eds). Nursing Nonprescription Drug Handbook. First Edition.

Lipincott Williams & Wilkins, Springhouse Division. Springhouse, PA. 2001-2005.

6. Page RL2. Bromelain. The Natural Pharmacist. http: www.tnp.com. December 2000.

(website no longer available as of 2005)

H. TEACHING ACTIVITY

1. Pharmacy/Nursing/Medicine/Dentistry Programs

a. School of Pharmacy, Undergraduate Program

PHPR 4610 – Pharmacotherapeutics II

Spring 1999, Spring 2000 ( 2 contact hour/semester),

Lecture topic: Contraceptives

PHPR 4300 – Nonprescription Drug Products (PBL facilitator)

Fall 1998 (3 sessions – 2 hours/ session)

PHPR 4400 – Introduction to Clerkship (facilitator for asthma, diabetes assessment)

Fall 1998 (1 session – 3 hours/session)

PHPR 4400 – Introduction to Clerkship (facilitator for asthma assessment)

Summer 1999, Fall 1999, Fall 2000 (1 session – 3 hours/session)

b. School of Pharmacy, Track-in Program

PRDO 5620 – Advanced Therapeutics and Kinetics III

Summer 1999-2002 (2 contact hours/lecture)

Lecture topic: Dermatological Pharmacotherapy

Lecture topic: Microvascular Complications in Diabetes

Lecture topic: Diabetic Foot Infections

PRDO 5420 – Advanced Therapeutics and Kinetics II

Spring 1999- 2001 (4 contact hours/ lecture)

Lecture topic: Osteomyelitis, Skin/Soft Tissue Infections

Lecture topic: Intra-abdominal Infections, Gastroenteritis

Lecture topic: Urinary Incontinence

Lecture topic: Drug Allergy

PRDO 5220 – Advanced Therapeutics and Kinetics I

Fall 1998 (5 contact hours/ lecture)

Lecture topic: Pharmacotherapy of Chronic Congestive Heart Failure

Lecture topic: Pharmacotherapy of Acute and Chronic Pancreatitis

http://www.tnp.com/

Fall 1999, Spring 2000(6 contact hours/lecture)

Lecture topic: Pharmacotherapy of Chronic Heart Failure

Lecture topic: Pharmacotherapy of Acute Heart Failure

Lecture topic: Pharmacotherapy of Acute/Chronic Pancreatitis

PRDO 5400 – Pathophysiology

Fall 1998 (1 contact hour/ lecture)

Lecture topic: Acute and Chronic Pancreatitis

Fall 1999, Spring 2000 (2 contact hours/ lecture)


Lecture topic: Cystic Fibrosis

PRDO 5600 - Pathophysiology

Spring 2001 (1 contact hour/ lecture)

Lecture topic: Painful Neuropathies

PRDO 5800 – Pathophysiology

Summer 2000 (1 contact hour/ lecture)

Lecture topic: Diabetic Foot

PRDO 5220/5400 –Advanced Therapeutics and Kinetics Skills Development

Fall 1998 (oral exams: GI & Cardiovascular Therapeutics) (4 hours/exam)

Fall 1999-2001 (oral exams: Cardiovascular Therapeutics)

(4 hours/exam)

PRDO 5250 – Professional Skills Development (GI & Cardiovascular Therapeutics)

Fall 1998 ( 27 contact hours); Fall 1999- 2000 (12 contact hours)

c. School of Pharmacy, Entry-level Program

PHRD 3600-Science Foundations

Fall 2008-2010 ( 2 contact hours/ lecture)

Lecture Topic: Aseptic Technique

PHRD 3410-Public Health, Economics, and Policy

Fall 2009-2011 (2 contact hours/ lecture)

Lecture topic: Role of the Pharmacist in Public Health

Lecture topic: Health Models within Community Settings

Lecture topic: Community Assessment/Needs Assessment Tools

PHRD 4300, 4350, 5300 - Experiential Portfolio Evaluator

2000- 2004 (1-6 students)

PHRD 4100—Professional Skills Development (Cardiology)

Lecture topic: Management of Heart Failure

Fall 2000-2011 (9 contact hours)

PHRD 4150- Professional Skills Development (GI Therapeutics)

Lecture topic: Management of Pancreatitis

Spring 2001-2004 (8 contact hours)

PHRD 4150- Professional Skills Development (CNS Therapeutics)

Lecture topic: Management of Insomnia

Spring 2002-2006 (8 contact hours)

PHRD 4700- Integrated Organ Systems (Cardiology)


Lecture topic: Hypertensive Emergencies

PHRD 4760- Integrated Organ Systems (Gastroenterology)

Spring 2001-2004 (4 contact hours/ lecture)


PHRD 4770-Intergrated Organ Systems (CNS)

Spring 2001-2004 (2 contact hours/ lecture)

Lecture topic: Pain Pharmacotherapy

Lecture topic: Insomnia/Anxiety

PHRD 4700- Pathophysiology (Cardiology)


Lecture topic: Pathophysiology of Cardiovascular Disease


Fall 2000- 2012 (9-11 contact hours/ lecture)

Lecture topic: Pharmacotherapy of Heart Failure (Acute/Chronic/Herbal)


Fall 2002-2009 (4-6 contact hours/ lecture)

Lecture topic: Pharmacotherapy of Dsyarrhythmias


Fall 2005-2011 (6-8 contact hours/ lecture)

Lecture topic: Acute Coronary Syndromes

PHRD 5480 – Pharm. D. Seminar (Faculty Preceptor)

Spring 1999-2013 (2 seminars/year)

PHRD 5550- Interdisciplinary Ethics

Spring 2010-2010 (10 contact hours/semester)

Lecture topic: Various topics

PHRD 5700 – Integrated Organ Systems (Endocrine)


Lecture topic: Diabetic Foot

PHRD 5700 – Integrated Organ Systems (Endocrine)

Fall 2002 (1 contact hours/ lecture)

Lecture topic: Adrenal Insufficiencies

PHRD 5650-Comprehensive Patient Care

Spring 2002- 2011 (14-18 contact hours/semester)

Lecture topic: Acute Cardiology

PHRD 5850-Geriatics Elective

Spring 2002-2004 (2 contact hours/lecture)

Lecture topic: Insomnia in the Geriatric Patient

PHRD 7400-Pharmacoeconomics

Fall 2010-2011 (2 contact hours/lecture)

Lecture topic: Drug Utilization Review

PHRD 6945-Public Health and Health Outcomes

Spring 2014-Present (1.5 contact hours/ lecture)

Lecture topic: Principles and Structure of Public Health

Lecture topic: Medicaid-Foundations and Principles

Lecture topic: Role of Pharmacy in Medicaid

Lecture topic: Exercise in Formulary Management

Lecture topic: Ethical Dilemmas Regarding Roles of Pharmaceutical Industry

Lecture topic: Drug Shortages/Access

Lecture topic: Principles and Models of Health Promotion and Prevention

Lecture topic: Cultural Competence

PHRD 6915- Research Seminar (4 students)

Spring 2014-Present

d. School of Pharmacy, Course Coordination

PRDO 5420 – Advanced Therapeutics and Kinetics II (Co-coordinator)

Spring 1999-2001. (4 course credits)

PRDO 5600 - Professional Skills Development (Co-coordinator)

Spring 1999-2001. (3 course credits)

PHRD 3150- Professional Skills Development- P1 (Co-coordinator)

Fall 2002-2007. (3 course credits)

PHRD 4720- Integrated Organ Systems - V


PHRD 4100- Professional Skills Development- P2 (Co-coordinator)


PHRD 3410-Public Health, Economics, and Policy

Fall 2009-2011 (2 course credits)

PHRD 7250-PharmD Seminar Course

Spring 2013 (2 course credits)

PHRD 6945-Public Health and Health Outcomes (Co-coordinator)

Spring 2014-Present (3 course credit)

e. School of Pharmacy, Nontraditional Program

PRDO 5350 – Advanced Disease State Management

Spring 1999, Spring 2000- 2001 ( 2 contact hours/lecture)

Lecture Topic: Cystic Fibrosis

PRDO 5320—Advanced Disease State Management


Lecture Topic: Soft Skin and Bone Infections/Surgical Prophylaxis

Lecture Topic: Intra-abdominal Infections

ADSM 7310—Cardiovascular and Renal

Spring 2011-Present (6 contact hours/lecture)

Lecture Topic: Acute Coronary Syndromes

f. School of Medicine, Physical Therapy, Masters Program

PHTR 6586- PT Management: Medical I


Lecture Topic: Introduction to Pharmacology

Lecture Topic: Review of Cardiovascular Therapeutics

g. School of Medicine, Physical Therapy, Doctor of Physical Therapy (DPT) Program

PHTR6850c- Pharmacology

Fall/Winter 2003-2005 (2 contact hours/lecture)

Lecture Topic: Introduction to Pharmacokinetics

Lecture Topic: Cardiovascular Pharmacology

Lecture Topic: FDA Regulation/Herbal Products

Lecture Topic: Drugs Affecting Movement

DPTR 6121- Pharmacology

Fall/Winter 2006-2013 (2 contact hours/lecture)





DPTR 8313- Pharmacology

Spring 2004-2009 (2 contact hours/lecture)





h. School of Medicine, Physical Therapy, DPT, Course Coordination

DPTR 6121- Pharmacology (Co-coordinator)

Fall 2005-2013 (1 course credit)

DPTR 8313-Pharmacology: Online Program (Co-coordinator)

Fall 2004-2009 (1 course credit)

i. School of Medicine, Doctor of Medicine Program

MED8029-Applied Clinical Pharmacology

Spring 2003-Present (2 contact hours/semester)

Lecture topic: Drug Interactions: Pumps, Proteins, and P450s

j. College of Nursing, Nurse Practitioner Program

NURS - Nurse Practitioner Pharmacology (Neuro-Psy Module)

Spring 2002-2004 (2 contact hours/semester)

Lecture topic: Pain Pharmacotherapy

k. School of Dentistry, Doctor of Dental Surgery Program

DSSD 6608- Medical Emergencies

Spring 2003-Present (2 contact hours/semester)

Lecture topic: Prevention and Management of Medical Emergencies

2. Residency/Fellowship Programs

a. Pharmacy Residents: Faculty Rotation , Medicine, Cardiology Rotations

Academic Year 1998 – 1999

Anne Zegafuse (2 months), Jamie Nash (1 month), Tim Todd (1 month),Priscilla Miller (1

month)

Academic Year 1999 – 2000

Susan Heilmann. (2 months), Julia Kelleher. (2 months), Kristal Morris( 1 month)

Academic Year 2000-2001

Dori Wilkey ( 2 months), Andrea Wessel l(2 months), Holly Hagen (2 month), Jennifer

McCullough (1 month)


Daniel Bestul (1 month), Carolyn Wang (1 month)Christine Rogers (1month), Megan Bewer

(2 months)


Donnie Nuzum (2 months), Ben Stately (1month), Carrie Cannella (2 months)

Nicole Schlobohm (2 months), Holly Brewster (1 month), Marilee Obritsch (1 month)


Sherri Zerr (2 months), Reza Kazerooni (1 month), Tyree Kiser (1 month), Debra Anderson

(1 month)


Kevin Potts (1 month), Jon Reily (1 month), Dana Hanamura (1 month), Paul Juang (1

month)


Gretchen Imel (1 month), Joe VandeGriend (1 month), James Landzinski (1 month), Joel

Marrs (1 month), Jonathan Gaubert (1 month)


Kenneth Utz (1 month), Dorothy Albright (1 month), Phillip Owen (1 month), Kelli Gibson

(1 month), Angela Dangler (1 month), Chelsea Hunter (1 month), Victor Lewis (1 month)


Erika Horinek ( 1 month)


Matthew Casiano (1 month), Jessica Leonard (1 month), Scott Mueller (1 month), Sarah

Anderson (2 months)


Jacob Langness (2 weeks), Sarah Carson (1 month), Alicia Mann (1 month), Lam Nygen (1

month), Lance Lindberg (1 month)


Lynn Annlicker (1 month), Kelly Schoeppler (1 month), Matt Hofferman (1 month)


Kelly Schoeppler ( 1 month), Courtney Shakowski (1 month), William King (1 month),

Charles Foster (2 weeks)


Courtney Shakowski (1 month), Paul Reynolds (1 month), Laura Baumgartner (1 month),

Demi McCashland (1 month), Jackie Chomicki (1 month)


Danielle Rhyne (1 month), Breanna Schmidt (1 month), Nikki Kelly (1 month), Lisa Hong (1

month), Laura Baumgartner (1 month)

b. Pharmacy Resident: Lectures

Pharmacy Practice Pharmacotherapy Forum:

2000-2009

Lecture topic: Review of Pharmacokinetics (1 hour/year)

Lecture topic: Making Sense of the Numbers: EBM (1 hour/year)

Lecture topic: Using Powerpoint for Effective Presentations (1 hour/year)

2000-Present

Lecture topic: Heart Failure Therapeutics (1 hour/year)

c. Pharmacy Resident: Research

Shakowski CK, Andrew Monte, Page RL2. Evaluation of Low Dose Droperidol on QTc

Prolongation in the Emergency Department. University of Colorado Hospital. 2012-2013.

Shakowski CK, Page RL2, Lin S, Lindenfeld JA. Proteinuria in Heart Transplant Recipients:

Incidence and Management. University of Colorado Hospital. 2011-2012.

King William, Page RL2, Klem P. Simvastatin Use in Transplantation: Medication Use

Evaluation. University of Colorado Hospital. 2011-2012.

Hafermann M, Seibold G, Page RL2. QT Prolongation Associated with Ondansetron in

Patients with Underlying Cardiac Disease. University of Colorado Hospital. 2010-2011.

Kiser T, Page RL2. Lindenfeld J. Evaluation of Phenytoin and Cyclosporine Drug

Interactions in Heart Transplant Recipients. University of Colorado Hospital. 2003-2004.

Wang C, Hemstreet B, Page RL2. Prospective Evaluation of “Sulfa” Allergy in an Inpatient

Medical Center. University Hospital. 2001-2002.

McCullough J, Page R2, Nair K, Ruscin JM. Evaluation of Heart Failure Pharmacotherapy

in a Geriatric Population. University Hospital. 2000-2001.

Bateman R, Hilts A, Page RL2, Madinger N. The Impact of fluconazole use on the

incidence of resistance in Non-Candida albicans species. University Hospital.

1998-1999.

Pollock S, Ruscin M, Bainbridge J, Page R2L. Concurrent use of cholinesterase inhibitors

and anticholinergic agents in patient’s with Alzheimer’s disease. University Hospital and the

Center for the Aging. 1998-1999.

Nash J, Steckline C, Page RL2, Klem P. Cost analysis of in-patient vs out-patient use of

enoxaparin for the treatment of DVT. University Hospital. 1998-1999.

d. Cardiology Fellows Curriculum: Lectures

Cardiology Fellows Monthly Seminar.

2001-Present (2 contact hours/semester)

Lecture topic: Review of Pharmacokinetics/dynamics

3. Doctor of Philosophy/Pharm.D Programs

a. PhD Student: Research

Slejko JF, Page RL2, Sullivan P. Statin Therapy is Cost-Effective for Vascular Event

Prevention in Adults with Elevated C-Reactive Protein: Implications of JUPITER. 2009-

2010.

b. Pharm.D Student: Research

Ross JL, Kiser TH, Page RL2. Serum Thiocyanate Levels In Critically Ill Patients Receiving

Sodium Nitroprusside Infusions. 2011-2012.

Shipp K, Page RL2, Keller K, Lindenfeld JA. Evaluation of the Use and Policies for

Medical Marijuana in Heart and Lung Transplant Recipients: A Survey of United States

Transplant Medical Directors. 2011-2012.

Wells D, Flynn K, Page RL2, Spencer AP. Effect of amiodarone on argatroban dosing.

2006-2007.

Vogel N, Page RL2. Retrospective evaluation of omega-3 fatty acids in heart transplant

recipients. 2006.

Sprik R, Page RL2, Ruscin JM. Comparison of internist versus cardiologist management of

heart failure in an university-based internal medicine clinic. 2001.

Miller S, Page RL2, Hammer D, Jarvis C. Development and implementation of a pharmacy

career development program. 2000.

Smith M, Thompson E, Knutson P, Maffeo C, Page RL2. Evaluation of the educational

quality of internship experiences at University Hospital. 1999.

4. Other Teaching

“Interviewing Skills Workshop.” American College of Clinical Pharmacy Spring Meeting. Reno,

NV. April 2013.

“Unlocking the Power of Your Medications.” Heart Failure University. University of Colorado

Hospital/Division of Cardiology. Aurora, CO. March 2012.

“Overview of Residency Programs/Midyear.” Co-moderator. Phi Lamda Sigma/ Student Chapter

of ASHP Residency Panel Dinner. Aurora CO. November 2011.

“Pressors and Inotropes: Policy Updates. Cardiology Nurses Skill Development. University of

Colorado Hospital. Denver, CO. January 2011.



“To the Beat of the Rhythm of the Heart: Update in Atrial Fibrillation. Cardiac Nurses In-

service. University of Colorado Hospital. Aurora, CO. March 2010.



“Career Path Roundtable Facilitator-Cardiology.” American College of Clinical Pharmacy Fall

Scientific Meeting. Anaheim, CA. October 2009.

“Getting to the Heart of Heart Failure: A Therapeutic Primer For Pharmacists.” Express Scripts-

American College of Cardiology. St. Louis, MO. September 2009.

“Life Beyond Pharmacy School”. UCHSC School of Pharmacy, Professional Career

Development Course. Denver, CO. November 2008.


of ASHP Residency Panel Dinner. Denver, CO. November 2008.

“Professionalism for the Medical Resident: Policy Update.” Department of Medicine Morning

Report. University of Colorado Hospital. Denver, CO. September 2008.





“Review of IV Vasoactive Agents”. Medicine Nurses Skill Development. University of Colorado

Hospital. Denver, CO. January 2007.

“Review of Antiarrthymic Medications in the ICU. Medicine Nurses Skill Development.

University of Colorado Hospital. Denver, CO. January 2007.

















“New Drug Update for the Emergency Medicine Practitioner.” Highlands Ranch Urgent Care.

Highlands Ranch, CO. August 2005.





“Update in Cardiovascular Pharmacotherapy For the Nurse Clinician”. Centennial AHEC.

Greely, CO. October 2004.

“The Role of ARBs in Systolic Dysfunction”. Congestive Heart Failure Core Committee.

University of Colorado Hospital Denver, CO. August 2004.

“Aldosterone Antagonism Post MI”. Internal Medicine Physicians. Anschultz Outpatient

Pavilion. Denver, CO July 2004.

“The ABCs of ARBs and ACE inhibitors in Systolic Dysfunction”. ICU/CCU nurses. University

of Colorado Hospital Denver, CO. January 2004.

“What is the Role of Beta Blockers in the ICU?” ICU/CCU nurses. University of Colorado

Hospital Denver, CO. March 2004.

“Lipid Pharmacotherapy: Formulary Update.” Medicine Nurses. University of Colorado

Hospital Denver, CO. February 2004.

“Update for the Management of Systolic Dysfunction”. ICU/CCU nurses. University of

Colorado Hospital Denver, CO. January 2004.

Minority Summer Enrichment Program: Careers in Pharmacy ( 2 contact hours). UCHSC School

of Pharmacy. Denver, CO. June 2003.





“Lipid Management for the ACS Patient.” ICU/CCU nurses. University of Colorado Hospital

Denver, CO. September 2003.

“Role of Vasopressin in the ICU”. ICU/CCU nurses. University of Colorado Hospital Denver,

CO. September 2003.

“How to Get a Pharmacy Practice Residency”. Co-lecturer. UCHSC, School of Pharmacy.

Denver, CO 2002. November 2002.





“Update on Argatroban”. Orthopaedic Nurses. University of Colorado Hospital. Denver, CO.

October 2002.

“Role of Sotalol/Review of Aminoglycosides/Vancomycin”. Medicine Nursing Staff Clinical

Skills Development. October 2002.



“Putting the Action in Drug Interaction”. Medicine/Cardiology Nursing Staff. University of

Colorado Hospital. Denver, CO. May 2002.

“Making Sense of the Numbers: Biostatics Update”. Faculty Journal Club. UCHSC, School of

Pharmacy. Denver, CO. February 2002.





“What is a Residency?” Co-Lecturer. UCHSC School of Pharmacy’s Careers’ Day. Denver, CO.

November 2001.



“Pharmacotherapy of Acute and Chronic Heart Failure: The Nursing Perspective.” CCU Nurses.

University of Colorado Hospital. Denver, CO. February 2000.

“Review of Diabetic Complications.” New Approaches in Diabetes Education Workshop.

University Hospital. Denver, CO. October 2000.

“Review of Diabetic Complications.” New Approaches in Diabetes Education Workshop.

University Hospital. Denver, CO. October 1999.

“Pharmacotherapy of Acute Dental Pain.” Dental Pain Workshop. University of Colorado Health

Sciences Center, School of Dentistry. Denver, CO. May 2000.



Career Development Seminar for Pharmacy Students/Glaxo Welcome: Career’s Pathways:

Coordinator. USCHC, School of Pharmacy. Denver, CO. 2000.

General Medicine Module/Level 1: Coordinator. Pharmacy Education Program. Pharmacists,

UCHSC University Hospital. Denver, CO. 1999-2002.



Cardiology Clerkship (093-542): Primary Preceptor. Bachelor of Science Students, College of

Pharmacy. MUSC. Charleston, SC. 1997.

Medicine Clerkship (0953-542): Primary Preceptor. Doctor of Pharmacy Students, College of

Pharmacy, MUSC. Charleston, SC, 1998.

“The Role of the Pharmacist in the Management of Heart Failure.” Revco & Kerr Drug Regional

Meeting. Summerville, South Carolina. January 1998.

“Biostatistics: Making Sense of the Numbers.” Medical University of South Carolina,

University Hospital. Charleston, South Carolina. January 1998.

The Diabetes Initiative of South Carolina. Community Pharmacists, USC & MUSC Colleges of

Pharmacy. Charleston, SC, 1998.

Pharmacology (095-456): Bachelor of Science Students, College of Pharmacy. MUSC.

Charleston, SC. February 1998. Topic: Heart Failure.

Advanced Therapeutics I, II, III (092-694, 092-695, 093-678). Doctor of Pharmacy Students,

College of Pharmacy, MUSC. Charleston, SC. 1996 – 1998. Topics: Psoriasis, Bone / Joint

Infections, Infective Endocarditis.

Pharmacology (068-621). Physician’s Assistant Students, College of Health Related

Professions, MUSC. Charleston, SC. 1996 – 1998. Topics: Dermatology, Hyperlipidemia,

Community & Hospital Acquired Pneumonia, Seizure Disorder.

Clinical Therapeutics (093-541). Bachelor of Science Students, College of Pharmacy. MUSC.

Charleston, SC. August 1997. Topic: Seizure Disorder.

“New Therapeutic Modalities in the Management of Heart Failure: a Pharmacist’s Perspective.”

Eckerd Pharmacy Regional Meeting. Charleston, South Carolina. August 1997.

“The Role of Digoxin in Heart Failure: Old Habit or Proven Therapy?” Medical University of

South Carolina, University Hospital. Charleston, South Carolina. January 1997.

I. CLINICAL ACTIVITY

Since 1998, I have received 40-50% salary support from University of Colorado Hospital to provide

clinical pharmacy services. From 1998-1999, I rounded with one of the Adult Internal Medicine

services for six months of the year which followed 10-30 floor patients. From 2000-2008, I rounded

for six months of the year with the Cardiology service which consisted of four cardiology teams

which followed up to 15 ICU patients and 15-30 floor patients for general cardiology and the 10-15

ICU patients for heart failure/transplant. From 2008-present, I currently round solely with the

Advanced Heart Failure and Heart Transplant Service, which follows 10-15 ICU patients and 5-10

floor patients. Year round, I currently conduct all pharmacy transplant evaluations for the heart

transplant service, attend all heart transplant selection meetings, and evaluate patients once weekly

in the heart transplant clinic. I remain on call for the Division of Cardiology year round for

pharmacotherapy related issues for both the outpatient and inpatient services. Over the year, I

precept 2 specialty critical care pharmacy residents (post-graduate year 2), 2-4 pharmacy practice

residents (post-graduate year 1), and 2-4 pharmacy students.

Since 2011, I have been receiving funding from a grant through the Colorado Department of Health

Policy and Financing which provides 20-40% salary support as Clinical Lead to oversee and run

their drug utilization review (DUR) program for Colorado Medicaid. I provide these services

throughout the entire year in which I assist with running all quarterly DUR board meetings;

developing their retrospective and prospective DUR program; implementing and developing

exclusionary criteria for their preferred drug list; and assisting with oversight of all clinical

pharmacotherapy modules.

J. HONORS/AWARDS

American College of Clinical Pharmacy, Clinical Practice Award (2013)

American College of Clinical Pharmacy. Volunteer Recognition. (2012)

University of Colorado Graduate School, Outstanding PhD Student (2010)

American College of Cardiology Volunteer Recognition. (2010)

American College of Clinical Pharmacy, Cardiology PRN Service Award (2010)

Graduate Marshall, MSPH Class 2009 (2009)

AcademyHealth: Public Health Systems Research Interest Group Student Award (2008)

American Society of Health Systems Pharmacists, Appreciation Award (2004)

UCHSC, Chancellor’s Teaching Award (2004)

Phi Lamda Sigma, UCHSC School of Pharmacy, Alpha Xi Chapter (2001)

Excellence in Teaching, UCHSC, Pharm.D. Class 2004 (2001)

Excellence in Teaching, UCHSC, Pharm. D. Class (1999)

UCHSC, President’s Teaching Award (1999)

The Ciba-Giegy Netter: Second Honor Graduate Award (1994)

The Smith-Kline Beecham Award for Outstanding Patient Care (1994)

The Mylan Pharmaceuticals Award for Excellence in Pharmacy (1994)

Kappa Psi Scholarship Honors Award (1994)

Who’s Who Among American Universities and Colleges (1993)

Rho Chi Honor Society (1993 )

MUSC Dean’s List, all semesters from (1991 – 1996)

Alpha Epsilon Delta, the Premedical Honor Society (1989)

K. INVITED SPEAKING/MODERATING ENGAGEMENTS

1. Local

“New Anticoagulants—What a Bloody Mess.” School of Medicine. Cardiology Grand Rounds.

November 2013.

“Beta Blockers Post-Heart Transplant”. Morbidity and Mortality Grand Rounds. University of

Colorado Hospital. Aurora, CO. March 2013.

“When Drug Therapy Gets Old.” Physical Medicine Resident Grand Rounds. University of

Colorado School of Medicine. Aurora, CO. January 2013.

“Statins-FDA Updates and Controversies. What you REALLY Need to Know.” Grand Rounds.

Department of Pharmacy, University of Colorado Hospital. Aurora, CO. June 2012.

“Newer Antiplatelet Therapies: Implications and Clinical Pearls”. Advanced Practice Practitioners

Forum. University of Colorado Hospital. Aurora, CO. February 2012.

“Living with Heart Failure: New Therapies to Beat Up Heart Failure” Mended Hearts. Porter

Adventist Hospital. Denver, CO. May 2011

“Polypharmacy-Focus on Physical Medicine.” Physical Medicine Resident Grand Rounds.

University of Colorado. Aurora, CO. May 2011.

“Evaluation of Polypharmacy in the Elderly.” Geriatric SAC. University of Colorado Denver.

Aurora, CO. March 2010.

“ACE-Inhibitor Conversion Policy and Procedure.” Pharmacy and Therapeutics Committee.

University of Colorado Hospital. Aurora, CO. March 2009.

“Valsartan.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Aurora,

CO. March 2009

“Bisoprolol”. Pharmacy and Therapeutics Committee. University of Colorado Hospital. Aurora,

CO. October 2008.

“Tricor.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Aurora, CO.

October 2007.

“Getting with the Guidelines: Core Measures in Heart Failure.” Longmont Hospital. Longmont,

CO. September 2007.

“Omacor.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Denver,

CO. February 2007.

“The Role of Pharmaceutical Industry in Medicine”. Medicine Resident Noon Conference.

Denver, CO. August 2006.

“When Natural Doesn’t Mean Safe: Pharmacotherapy in Transplant Patient.” Denver Transplant

Nurses Association. Denver, CO. July 2006.

“Update in the Evolution of Chronotherapy.” Colorado Pharmacists Society. Humma, CO.

October 2004.

“Chronotherapy in the Geriatrics Patient.” Swedish Hospital. Division of Gerontology. Denver,

CO. October 2004.

“Putting Your Heart Into It: Update in Cardiovascular Pharmacotherapy.” Boulder Community

Medical Center. Boulder, Colorado. August 2004.

“Atacand.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Denver,

CO. August 2004.

“Crestor.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Denver, CO.

August 2004.

“Only Time Will Tell: The Pharmacotherapy Behind Chronotherapy”. Colorado Pharmacists

Society. Colorado Springs, CO. April 2004.

“What’s Old, What’s New, and What’s Next: An Evidenced-Based Review of Statin

Pharmacotherapy.” Colorado Pharmacists Society. March 2004.

“The Evolving Role of the “New” DMARDs in Clinical Practice: Enthusiasm Tempered with

Caution?” Advances in Pharmacy Practice Symposium. Denver, CO. February 2004.

“Inspra.” Pharmacy and Therapeutics Committee. Univeristy of Colorado Hospital. Denver, CO.

December 2003.

“Taking the Failure out of Heart Failure.” Geriatric Ground Rounds. VA Medical Center. Denver,

CO. November 2003.

“Taking the Failure out of Heart Failure: Pharmacist’s Role in Beta Blockade”. Colorado

Pharmacist Society/Walgreens/Kings Soopers. Denver, CO. September 2002.

“New Medications for Pain Management in the Orthopaedic Patient.” National Association of

Orthopaedic Nurses, Denver Chapter. Denver, CO. August 2002.

“Natrecor.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Denver,

CO. January 2002.

“Update on Alternative Medications for the Orthopaedic Patient.” Orthopaedic Grand Rounds.

Presbyterian Saint Luke’s Hospital. Denver, CO. March 2001.

“Herbal Update: Pharmacotherapy for the Aches and Pains.” Southern Society of Health Systems

Pharmacists. Pueblo, CO. December 2001.

“Therapeutic Update: Cox II Inhibitors-New Data”. MediLife Pharmacy of Colorado. Denver,

CO. November 2000.

“Review of Potentially Hazardous Statin Interactions.” Denver Veterans’ Administration Medical

Center. Denver, CO. November 2000.

“Management of Drug-Nutrient Interactions.” Association of Consultant Dietitians.

Lakewood, CO. June 2000.

“Adverse Reactions and Safety Profile of the Statins.” Colorado Pharmacists Society. Denver,

CO. March 2000.

“Tikosyn.” Pharmacy and Therapeutics Committee. University of Colorado Hospital. Denver,

CO. August 2000.

“A Review of the Lipid Trials: Understanding the Numbers Needed to Treat.” Department of

Medicine. University of Colorado School of Medicine. Denver, CO. November 1998.

2. State

“Heart Failure with Preserved Ejection Fraction: The Other Heart Failure.” Colorado Pharmacist

Society Annual Meeting. Colorado Springs, CO. May 2013.

“Current and Potential Cost Saving Analysis for Proton Pump Inhibitor Policy Changes.”

Department of Health Policy and Finance-DUR Board. Denver, CO. May 2013.

“Psychotropic Medication Use in Colorado Medicaid Children and Adolescents: A Focus on

Foster Children. Department of Health Policy and Finance-DUR Board. Denver, CO. February,

2013.

“Analysis of Proton Pump Inhibitors: Utilization, Cost, and Potential Interventions with a Focus

on Non-preferred PPI Use and Patients with GERD in Colorado Medicaid Beneficiaries.

Department of Health Policy and Finance-DUR Board. Denver, CO. May 2012.

“Drug Interactions 101-A Case-Based Approach to Cardiovascular Drug-Drug Interactions.

Colorado Pharmacists Society. Beaver Creek, Colorado. January 8. 2012.

“Drug-Drug Interactions with Radiopharmaceuticals.” Rocky Mountain Nuclear Medicine

Technologist Association Annual Meeting. Denver, Colorado. October, 2010.

“Controversies in Cardiology: Trials and Fibrillation.” Rocky Mountain Hospital Medicine

Symposium. Denver, CO. October 2010.”

“Making Sense of the Data: Update in Cardiology.” Colorado Pharmacists Society Summer

Meeting. Estes Park, CO. June 2010.

“Atrial Fibrillation: Opportunities and Challenges. North Carolina Pharmacists Association.

Chronic Care Practice Forum Meeting. Concord, NC. March 2010.

“Trials and Tribulations: An Update in Cardiology Controversies.” North Carolina Pharmacists

Association. Chronic Care Practice Forum Meeting. Concord, NC. March 2010.

“Herbal Supplements for the Osteoarthritis and Low Back Pain: Part 1.” American Physical

Therapy Association-Rocky Mountain Region. Colorado Springs, CO. November 2009.

“Herbal Supplements for the Osteoarthritis and Low Back Pain: Part 2.” American Physical

Therapy Association-Rocky Mountain Region. Colorado Springs, CO. November 2009.

“Understanding the Mysterious “Broken Heart”: A Pathophysiological Review of the

Management of Heart Failure.” Rocky Mountain Nuclear Medicine Technologist Association

Annual Meeting. Denver, Colorado. October, 2009.

“Clinical Controversies in Cardiology and Anticoagulation”. Rocky Mountain Hospital Medicine

Symposium. Denver, CO. October 2009.”

“Demystifying the Principles of Pharmacokinetics and Pharmacodyanmics : A Primer for New

Medicine Technologists.” Rocky Mountain Nuclear Medicine Technologist Association Annual

Meeting. Denver, Colorado. October, 2008.

“Pharmaco-what? Pearls in Pharmacology for the Practicing Physical Therapist.” American

Physical Therapy Association-Rocky Mountain Region. Denver, CO. October 2007.

“Fun Pharmacy Facts.” Kidney Camp-National Kidney Foundation of Colorado and Wyoming.

Winter Park, CO. August 2007.

“Clinical Pearls: Focus on Diastolic Dysfunction. Rocky Mountain Hospital Medicine

Symposium. Denver, CO. October 2006.

“Hot off the Press :Late Breaking Clinical Trials in Cardiovascular Pharmacotherapy. Colorado

Pharmacist Society Annual Meeting. Denver, CO. October 2006.

“Straight from the Heart: Clinical Pearls in the Management of the Cardiovascular Patient.

Colorado Pharmacist Society Annual Meeting. Denver, CO. October 2005.

“Clinical Pearls from the Heart: Focus on Heart Failure. Rocky Mountain Hospital Medicine

Symposium. Denver, CO. October 2004.

“Current Controversies in Cardiology: Implications for Pharmacists.” Colorado Pharmacist

Society Annual Fall Meeting. Denver, CO. October 2004.

“When Natural Doesn’t Always Mean Safe: Herbal Pharmacotherapy in the ESRD Patient.”

American Association of Nephrology Nurses. Breckinridge, CO. May 2004.

“The Pharmacotherapy Behind Chronotherapy: Implications for Pharmacists?”

South Dakota Pharmacists Association. Grand Rapids, South Dakota June 2004.

“The Role of Chronotherapy in Cardiovascular Disease.” Wyoming Pharmacists Society.

Cheyenne, Wyoming. April 2004

“Putting Your Heart into It: Update in Cardiovascular Pharmacotherapy." Colorado Pharmacists

Society Annual Meeting; Denver, CO. October 2003.

"Update Men’s Health: Drug Therapy for the 30 Something Guy." Colorado Pharmacist Society

Annual Meeting. Denver CO. October 2003.

“Taking the Failure out of Heart Failure: New and Future Pharmacotherapies”. Colorado

Pharmacist’s Society Annual Meeting. Denver, CO. October 2002.

“New Drug Update For the Orthopedic Patient “. National Association of Orthopedic Nurses-

Denver Chapter. Denver, CO. March 2002.

“Alternative Pharmacotherapies in Cardiovascular Medicine”. Kaiser Permanente. Portland, OR.

December 2002.

“The Phantom Menace: Coxib Cardiotoxicity”. Oregon Society of Health System Pharmacists.

Portland, OR. May 2002.

“COX-2 Update: Has Promise Become Reality?” Inter-Mountain Health. Salt Lake City, UT.

November 2001.

“Medication Errors in the Elderly”. ASHP, State Spokesperson for Medication Errors. Radio

Interviews. Colorado. October 2001.

“Medication Errors in the Elderly”. ASHP, State Spokesperson for Medication Errors. Radio

Interviews. Wyoming August 2001, October 2001.

“COX-2 Technology: Has Promise Become Reality.” National Association of Nurse Practitioners

(Denver Chapter). Radisson Hotel. Denver, CO. March 2001.

“Update in COX-2 Technology.” Nevada Family Medicine Association, Annual Meeting.

SunCoast Hotel. Las Vegas, Nevada. September 2001.

“New Drug and Herbal Therapies for the Physical Therapy Patient; Medication Pitfalls.”

Colorado Physical Therapy Society Annual Symposium. St. Anthony’s Hospital. Denver, CO.

November 2000.

“New Drug Update—Tikosyn.” Colorado Society of Health Systems Pharmacy Annual Meeting,

DIA Holiday Inn. Denver, CO. November 2000.

“The Importance of Medication Errors”. ASHP, State Spokesperson for Medication Errors.

Radio Interviews- Denver, Fort Collins. October, November 2000.

“New Innovations in the Management of Heart Failure.” Colorado Society of Health Systems

Pharmacy Annual Meeting, DIA Holiday Inn. October 1999.

“When Natural Doesn’t Mean Safe”. ASHP, State Spokesperson for Medication Errors. Radio

Interviews- Denver, Winter Park, Pueblo, Colorado Springs. March 1999.

5. National

“Interprofessional and Patient Centered Care-Applying Theory to Practice.” American College of

Clinical Pharmacy Spring Meeting. Chicago, IL. April 2014.

“Antiplatelet Therapy—Types, Doses, and Platelet Function Assays/Targets.” International Heart

and Lung Transplant Scientific Sessions. San Diego, CA. April 2014.

“To Digitalize or Not” ”(Panelist). American College of Cardiology Scientific Sessions. Chicago,

IL. March 2014.

“Pharmacologic Considerations in Post-Transplant/LVAD Patient”(Panelist). American College of

Cardiology Scientific Sessions. Chicago, IL. March 2014.

“Ask the Experts: Controversies and Challenges in Heart Failure Pharmacology.” (Moderator).

American Heart Association Scientific Sessions. Dallas, TX. November 2013.

“Cardiovascular Pharmacology: 2013 Update.” American Heart Association Scientific Sessions.

Dallas, TX. November 2013.

“The Role of Medication Reconciliation.” Heart Failure Society of America Annual Scientific

Meeting. Orlando, Florida. September 2013.

“Polypharmacy and Drug Interactions in the Frail Elderly with Heart Failure.” Heart Failure Society

of America Annual Scientific Meeting. Orlando, Florida. September 2013.

Pharmacokinetics/Pharmacodynamics: Implications for the Heart Failure Patient. American

Association of Heart Failure Nurses. Montreal, Canada. June 2013.

Medical Management of Ventricular Arrhythmias. American Association of Heart Failure

Nurses. Montreal, Canada. June 2013.


Clinical Pharmacy Spring Meeting. Reno, NV. April 2013.

“Meet the Experts-Which Drip for Which Patient.” (panelist). American College of Cardiology

Scientific Sessions. San Francisco, CA. March 2013

“Vitamin D Supplementation: Fleeting Fad or Abiding Benefits” (panelist). American College of

Cardiology Scientific Sessions. San Francisco, CA. March 2013.

“Integrated Telehealth And Care Management Program Reduces All Cause Mortality In

Medicare Beneficiaries With Heart Failure. “(platform presentation). American Heart

Association Scientific Sessions. Los Angeles, CA. November 2012.

“Economic Burden Of Acute Coronary Syndromes For Employees And Their Dependents:

Medical And Productivity Costs. “(platform presentation). American Heart Association

Scientific Sessions. Los Angeles, CA. November 2012.

“Demystifying Complementary and Alternative Medicine in Prevention of CVD.” (Moderator).

American Heart Association Scientific Sessions Los Angeles, CA. November 2012.

“Prevention and Management of Drug-Induced Cardiovascular Diseases.” (Moderator).

American Heart Association Scientific Sessions Los Angeles, CA. November 2012.

“Hypotension in the Elderly Patient.” American Heart Association Scientific Secessions Los

Angeles, CA. November 2012.

“ Do They Work? Proven and Likely CVD Benefits of Complementary and Alternative

Medicines.” American Heart Association Scientific Sessions Los Angeles, CA. November 2012.

“Is Warfarin Era Over? New Antithrombotic Agents.” American Heart Association Scientific

Secession. Los Angeles, CA. November 2012.

“The Art and Science of Preparing for Board Certification.” American Society of Health System

Pharmacists Great eXpectations Conference. Denver, CO. May 2012.

“Engage in Scholarly Activity: Research, Publications, and Presentations.” American College of




“Cardiology III”. BCPS Review. American College of Clinical Pharmacy. Spring Meeting.

Reno, NV. April 2012.

“Heart Failure Care for the Very Old: What Are the Key Issues for Success?” American College

of Cardiology Scientific Sessions. Chicago, IL. March 2012.

“Dyslipidemia and Residual Risk: When and How Do You Add to Statin Therapy? “(Panelist)

American College of Cardiology Scientific Sessions. Chicago, IL. March 2012.

“Improving Clinical Outcomes and Patient Safety Through Interventions by Clinical

Pharmacists.” (Moderator). American Heart Association Scientific Secessions. Orlando, FL.

October 2011.

“Prevalence of Major Comorbidities in Heart Failure Low Ejection Fraction and Preserved

Ejection Fraction.” Heart Failure Society of America Scientific Meeting. Boston, MA.

September 2011.

“Strike before Stroke: Intervening Early in Patients with Atrial Fibrillation: IDEALP2P

Telephonic Teaching Rounds Updates.” American Heart Association. July 2011.

“Cutting Edge Pharmacotherapy in Acute Care.” American Society of Health System Pharmacy.

Summer Meeting. Denver, CO. June 2011.

“Pharmacotherapy of Acute Decompensated Heart Failure” American College of Cardiology

Scientific Secessions. New Orleans, LA. April 2011.

“Outpatient Cardiology”. BCPS Review. American College of Clinical Pharmacy. Spring

Meeting. Columbus, OH. April 2011.


Clinical Pharmacy Spring Meeting. Columbus, OH. April 2011.

“ Clinical Practice Guidelines You Need to Know Now.” American Health System Pharmacists-

Great eXpectations eConference. April 2011.

“Job Finding/Marketing Yourself in a Competitive Market.” American Health System

Pharmacists-Great eXpectations eConference. April 2011.

“Strike Before Stroke: Intervening Early in Patients with Atrial Fibrillation.” American Heart

Association Scientific Secessions. Chicago, IL. November 2010.

“Effect of a city-wide smoking ban on maternal smoking prevalence and risk of preterm and low

birth weight births: The Colorado experience.” (platform presentation) American Public Health

Association Scientific Secession. Denver, CO. November 2010.

“Developing Effective Poster Presentations.” American College of Clinical Pharmacy Spring

Meeting. Charlotte, NC. April 2010.

“Reducing Stroke Risk in Older Adults with Atrial Fibrillation Managing Atrial Fibrillation in Older

Adults.” Co-presenter: Steven A. Rothman, MD, FACC. American Society of Consultant

Pharmacists Annual Meeting. Orlando, Florida. November 2010.

“Keeping a Steady Beat: Practical Strategies for Managing Atrial Fibrillation in Older Adults.”

Co-presenter: Steven A. Rothman, MD, FACC. American Geriatric Society Scientific Meeting.

Orlando, Florida. May 2010.

“Theory of Interprofessional and Patient Centered Care.” American College of Clinical Pharmacy

Spring Meeting. Charlotte, NC. April 2010.


Meeting. Charlotte, NC. April 2010.

“Cardiology and Diabetes Update: A Case Based Approach.” American Society of Consultant

Pharmacist Annual Meeting. Anaheim, CA. November 2009.

“Preventing Venous Thromboembolism: Approaches for Long-Term Care.” Co-presenter: Jack

Ansell, MD, FCCP. American Society of Consultant Pharmacist Annual Meeting. Anaheim, CA.

November 2009.

“Therapeutic Approaches to Atrial Fibrillation: Challenges and Opportunities for

the Consultant Pharmacist.” Co-presenter: Steven A. Rothman, MD, FACC

American Society of Consultant Pharmacist Annual Meeting. Anaheim, CA. November 2009.

“The Devil Wears Prada: Becoming A Competitive New Practitioner In A Highly Competitive

Market.” American Society of Health System Pharmacists Clinical Midyear Meeting-Great

eXpectations Conference. Las Vegas, NV. December 2009.

“Don’t Go Breakin My Heart: Cardiology Pearls for the Pharmacy Practitioner.”

American Society of Health System Pharmacists Clinical Midyear Meeting-Great eXpectations

Conference. Las Vegas, NV. December 2009.

“The Golden Compass: Finding Direction in Preparing for the BCPS Exam.” American Society

of Health System Pharmacists Clinical Midyear Meeting-Great eXpectations Conference. Las

Vegas, NV. December 2009.

“Is this ‘Beers’ For You: Utilization of the Beer’s Criteria in Evaluating Inappropriate

Prescribing in the Elderly.” American Society of Health System Pharmacists Clinical Midyear

Meeting. Las Vegas, NV. December 2009.


Meeting. Orlando, FL. April 2009.

“Confronting the Challenges of Anticoagulation Therapy: New and Emerging Research”.

American Society of Health System Pharmacy Clinical Midyear Meeting. Orlando, FL.

December 2008.

“Best in Session: Medicare Beneficiaries With Mild To Severe Heart Failure See 15-23 Different

Providers Annually.” American Heart Association Scientific Secessions. New Orleans, LA.

November 2008. Also available at:

http://scientificsessions.americanheart.org/portal/scientificsessions/ss/bestofsessions2008

“Evidence-based Guidelines, Performance Measures, Quality Indicators: How Do They Apply to

Elderly Patients on Antithrombotic Therapy?” American Society of Consultant Pharmacist

Annual Meeting. New Orleans, LA. November 2008.

“Tailoring Antiplatelet Therapy to Reduce Atherothrombosis in Elderly Residents”. Co-presenter

Clive Rosendorff, MD, PhD, FACC, FAHA. American Society of Consultant Pharmacists

Annual Meeting. New Orleans, LA. November 2008.

“Optimizing the Management of Heart Failure in Older Adults.” American Society of Consultant

Pharmacists Annual Meeting. New Orleans, LA. November 2008.

“Going the Distance: Preparing for the BCPS Exam.” American Society of Health Systems

Pharmacists-New Practitioners Program. Webinar. August 2008.

“Statins, Resins, and Other Enzyme Inhibitors: The Complexities of Lipid Management in the

CKD Patient.” National Kidney Foundation Scientific Meeting. Dallas, TX. April 2008.

“Heart Transplant 101-Drug Induced Complications.” American College of Clinical Pharmacy

Spring Meeting. Phoenix, AZ. April 2008.

“Herbals Should be Used in Patients with Heart Failure.” American College of Clinical

Pharmacy Annual Fall Meeting. Denver, CO. October 2007.

“The Devil in the Details: Pain Management in the Transplant Patient”. International Transplant

Nurses Scientific Congress. Denver, CO. October 2007.

“Exploring the Complexities of Antiplatelet Therapy in ACS: A Pathophysiological and

Evidence-based Perspective.” Case Management Society of America National Meeting. Denver,

CO. June 2007.

“Healing a Broken Heart: Update in ACS Pharmacotherapy” City of Hope 31th Annual Rationale

Therapeutics Seminar in Medicine. Anaheim, CA. June 2007.

“Critically Evaluating Evidence Addressing Current Controversies: Heart Failure”. American

Society of Health Systems Pharmacists Annual Summer Meeting. Orlando, FL. June 2006.

“The Devil in the Details: Rationale Therapeutics for the ACS Patient”. City of Hope 30th

Annual Rationale Therapeutics Seminar in Medicine. Anaheim, CA. June 2006.

“When Natural Doesn’t Always Mean Safe: Herbal Pharmacotherapy in the ESRD Patient.”

National Kidney Foundation Annual Meeting. Chicago, IL. May 2006.

“Meeting the Challenges of Hypertension in the ESRD Patient.” National Kidney Foundation

Annual Meeting. Chicago, IL. May 2006.

“Review of Herbal Pharmacotherapy for the Renal Dietician.” National Kidney Foundation

Annual Meeting. Chicago, IL. May 2006.

“Evolution of Heart Failure Pharmacotherapy”. Ohio State Colleges of Pharmacy and Medicine.

Columbus, OH. December 2005.

“Evidenced Based Medicine: Cardiology Update”. American Society of Health System

Pharmacists Clinical Midyear Meeting. Las Vegas, NV. December 2005.

“CSI: Highlights from the 7th American College of Chest Physician’s Conference on

Thrombolytic Therapy: Evidenced Based Guidelines.” New Drug Update. Charleston, SC April

2005.

“Using Off Label Medications in the Inpatient Setting”. American College of Clinical Pharmacy

Annual Fall Meeting. Dallas, TX. October 2004.

"Eplereone: Spironolactone Reloaded. American Society of Health Systems Pharmacists Clinical

Midyear Meeting; New Orleans, LA. December 2003.

“Putting Your Heart Into it: Update of Cardiovascular Pharmacotherapies”. National

Association of Orthopaedic Nurses Annual Congress. Las Vegas, NV. May 2002.

“What Have I Gotten Myself Into: Time Management Skills for the New Practitioner.” ASHP

Clinical Midyear Meeting. New Orleans, LA. December 2001.

“How Do I Get Started?” ASHP Student Forum. Student Leadership Session.

ASHP Clinical Midyear Meeting. New Orleans, LA. December 2001.

“Pharmacotherapy in the Older Adult.” Gerontological Society of America Scientific Meeting.

Chicago, IL . November 2001.

“Chapter Development for Faculty and Student Liaisons. American Society of Health System

Pharmacists Student Forum, American Society of Health System Pharmacists Annual Meeting,

Los Angeles, CA. June 2001.

“Older Drugs with Newer Indications: Implications for the Geriatric Patient.” American Geriatrics

Society Annual Scientific Meeting. Chicago, IL. April 2001.

“When Depression Leads to Heart Break.”. American Society of Health System Pharmacists


“New Drug Therapies in the Management of the Orthopaedic Patient.” National Association of

Orthopaedic Nurses Annual Congress. Denver, CO. May 2000.

“What is a Specialty Residency?” American Society of Health System Pharmacists Student

Forum. American Society of Health System Pharmacists Clinical Midyear Meeting. Orlando, Fl.

December 1999.

“Does Natural Mean Safe?”. ASHP, National Spokesperson for Alternative Medications. Radio

Interviews-Portland, Oregon; New York, New York; Greenville, North Carolina; Burlington,

Vermont. March-April 1999.

“How to Set up a Pharmacotherapy Specialty Residency.” Round Table Presentation.

American College of Clinical Pharmacy. Phoenix, Arizona. November 1997.

6. International

“Burden of Comorbidities And Medication Complexity In Heart Failure Patients Significantly

Increases Over A Single Decade.”(platform presentation) European Society of Cardiology-Heart

Failure Congress. Belgrade, Serbia. May 2012.

“Heart Failure As A Major Cause Of Prolonged Wound Healing And Increased Healthcare Cost

In Older Adults With Chronic Wounds.” (platform presentation) European Society of

Cardiology-Heart Failure Congress. Belgrade, Serbia. May 2012.

“A Lifecycle Journey in Advanced Heart Failure and Transplantation”. International Society of

Heart and Lung Transplantation.” Prague, Czech Republic. April 2012.

L. ADMINISTRATIVE ACTIVITY/UNIVERISTY SERVICE

1. School of Pharmacy Committees

Member, Faculty Search Committee-Oncology Faculty-Department of Clinical Pharmacy

2013-2014

Vice-chair, Distance Degree Learning

2013-Present

Member, Distance Degree Learning Committee (formally Non-traditional PharmD Committee).

2012-Present

Chair, Faculty Search Committee-Department of Clinical Pharmacy

Critical Care Faculty

2010-2011

Member, Advancement & Tenure Guidelines Task Force

2010-2012

Member, Test Policy Task Force

2010-2011

Member, Staff Search Committee-Office of Student Services

2009


Hematology/Oncology, Ambulatory Care Faculty Members

2008-2009


Director of Clinical Affairs

2007- 2008

Member, Advancement & Tenure Committee,

Department of Clinical Pharmacy

2006- 2007

Chair, Scholastic Academic Appeals Committee

2005-2010

Member, Scholastic Academic Appeals Committee

2003-2011

Member, Nine News Health Fair Task Force, School of Pharmacy

2003-2004

Faculty Delegate, American Association of Colleges of Pharmacy Annual Meeting

2002

Faculty Alternate, American Association of Colleges of Pharmacy Annual Meeting

2001

Member, Awards and Scholarships Committee

1998-2005

Member, ACPE Self-study Task Force - Practice Facilities

2001-2004

Group Leader, DOPP Faculty Strategic Plan Task Force (Patient Care)

2000- 2001

Member, Remediation Task Force

1999 –2001

Member, Pharm. D. Clerkship Committee

1999 – 2003

Member, Professional Skills Development Task Force

1999 – 2009

Member, Pharmaceutical Care Learning Center Task Force

1998 – 1999

Member, Oral Exam Subcommittee

1999 –2002

Member, Faculty Search Committee- Department of Pharmacy Practice

Internal Medicine Faculty Member

1999

2. School of Medicine Committees

Member, MSPH Policy Committee, Department of Preventive Medicine.

2007- 2008

Co-chair, Department of Medicine Professionalism Committee

2005- 2008

3. University of Colorado Hospital Committees

Member, Heart Failure Advanced Certification Committee-JCHO Committee

2012-Present

Member, Heart Transplant Selection Committee.

2010-Present

Member, ACC Hospital to Home (H2H) Core Committee.

2010-2013

Member, AHA Get with the Guidelines Committee. AMI and Heart Failure.

2003- 2010.

Member, Hospital Anticoagulation Committee

2005-2008

Chair, Inpatient Stain Conversion Committee

2004-2006

Member, Heart Failure Standards- JCHO Committee

2004-2008

Member, Pharmacy Practice Residency Council

2003-2008

Member, Acute Myocardial Infarction/Acute Coronary Syndrome Pathway

2003-2008

Interim Director, Pharmacy Practice Residency

2002- 2003

Member, Clinical Pharmacy Specialist Committee

2000 - 2010

Member, Congestive Heart Failure Pathway.

1998 -2001

Chair, General Medicine Pharmacist Credentialing Committee.

1998 - 2008

Member, Food Drug Interaction Committee

1999 – 2009

4. State Organization Committees

Colorado Medicaid Drug Utilization Review Committee. Colorado Department of Health Care

Policy and Financing

Chair: 2010- 2011.

Member: 2005- 2011.

Colorado Medicaid Pharmacy and Therapeutics Committee. Colorado Department of Health

Care Policy and Financing

Member: 2007- 2011

Vice-Chair: 2010- 2011

Colorado Society of Health System Pharmacists

Member: Board of Directors - School of Pharmacy Representative. 2000-2003

Chair: School of Pharmacy Program. 1999- July 2004.

Member: Annual Meeting Planning Committee. 1999-2005

Member: Scholarship Committee. 1999-2001

Member: Publicity Committee. 1999-2000

Think About it Colorado

Member: Board of Advisors. 2013-Present

7. National Organization Committees

American Public Health Association.

Member: Abstract Review Committee. 2010.

American Heart Association

Chair: Committee on Clinical Pharmacology. 2009-2013

Past-Chair: Committee on Clinical Pharmacology: 2013-2014

Member: Leadership Committee-Council of Clinical Cardiology. 2009-2013

Member: Program Committee-Council of Clinical Cardiology. 2009-2013

Member: Proposal Committee: AHA Summit on Pharmacy, January 2011.

Member: Writing Committee: Evolution of Critical Care Cardiology and the Emerging

Need for New Staffing and Training Models. 2011-2012.

Member: Drug Formulary Position Statement Committee. 2011

Chair: Writing Committee: Drugs to be Used with Caution or Avoided in Patients with

Heart Failure. 2012-2014.

Voting Member: Liaison from the American Heart Association to the United States

Pharmacopeia (USP). 2011-Present

Member: Writing Committee: Acute Coronary Syndrome and Renal Disease-

Considerations for Pharmacotherapy. 2012-2014

Member: Atrial Fibrillation Educational Advisory Task Force. 2012-2013.

Member: FDA Patient-Focused Drug Development Initiative. 2012-2013

Member: Get With the Guidelines-Atrial Fibrillation. 2012-Present

Member: Get With the Guidelines Steering Committee. 2013-2015.

Reviewer: 2013 ACCF/AHA/HRS Guideline for the Management of Patients with Atrial

Fibrillation. 2013

Member: Committee on Scientific Sessions Program. 2013-3014.

American College of Cardiology:

Member: Pharmacy Membership/Involvement Working Group. 2004-2005

Member: Writing Committee Health Policy Statement: Therapeutic Substitution. 2011

Member: Prescription Drug User Fee Act Renewal Working Group. 2011.

Member: FDA-ACC NSURE Working Group. 2012-2013.

American College of Clinical Pharmacy

Chair: Best Poster ACCP Annual Meeting. 2008.

Chair: Cardiology PRN. 2008-2009.

Chair-Elect: Cardiology PRN. 2007-2008.

Member: StuNet Planning Committee. 2007.

Secretary-Treasurer: Cardiology PRN. 2006-2007.

Chair: Task Force on Interprofessional Education. 2007.

Member: Abstract Review Committee. 2005-Present

Member: Board Certification Affairs Committee. October 2004-2006.

Co-Chair: Adult Medicine/Ambulatory Care PRN Annual Meeting Planning

Committee. 2004-2005.

Member: Cardiology PRN Poster Reviewer. 2004-2009.

Chair: Adult Medicine PRN-Nominations Committee. October 2004-2005.

Member: Cardiology PRN H2H Writing Committee. December 2010-2011.

Member: Cardiology PRN Pharmacy White Paper with HSFA. 2011.

Reviewer: Update in Therapeutics: BCPS Review. 2010-2011.

Reviewer: Clinical Reasoning Series. 2011.

Faculty Chair/Editor: PSAP VIII Cardiology/Endocrine. 2012-2013.

Member: Cardiology PRN Nominations Committee. 2013-2014.

American Pharmacists Association

Member: Board of Pharmaceutical Specialties. Role Delineation Task Force. 2009 –

2010.

Member: Board of Pharmaceutical Specialties. Item Writing Panel. 2001-2010.

Member: Board of Pharmaceutical Specialties. Pharmacotherapy Bank Maintenance

Task Force. 2007-2010.

Member: Board of Pharmaceutical Specialties. BPS Cardiology Pharmacy Practice

Analysis Taskforce. 2012-2013.

American Society of Consultant Pharmacists

Member: Abstract Reviewer. 2012.

American Society of Drug Utilization Review

Member: Program Committee. 2012-2013.

American Society of Health Systems Pharmacists

Member: New Practitioners Advisory Council. 2001-2003

Member: Nominations Committee-Council for Clinical Specialist 2011-Present

Heart Failure Society of America

Member: Nominations Committee. 2013-Present

Member: Scientific Session Planning Committee. 2011- Present

Member: Abstract Reviewer. 2012-Present

8. International Organization Committees

International Society of Heart and Lung Transplantation

Member: Clinical Pharmacy and Pharmacology Council Exploration Work Group.

2010.

Member: Clinical Pharmacy and Pharmacology Leadership Council. 2011-2014

Chair: Development of a Core Competency Position Statement for Thoracic Transplant

Pharmacy Professionals White Paper. 2011-2013.

Member: Corporate Development Committee. 2012-2014

Member: Abstract Reviewer. 2011-2013

M. PROFESSIONAL ACTIVITY AND PUBLIC SERVICE

1. Membership/Service to Professional Organizations

American Society of Drug Utilization Review (2012-Present)

United States Pharmacopeia (appointed member for AHA). 2012-2015

International Society of Heart and Lung Transplantation. Member (2010-Present)

AcademyHealth. Member (2008-2012)

National Lipid Association. Member (2007-2012)

Society of Geriatric Cardiology, Fellow (2006-2009)

American Society of Consultant Pharmacists, Fellow (2005-Present)

Heart Failure Society of America, Member (2004-Present)

Phi Lamda Sigma, Member (2001-Present)

American Heart Association, Premium Member (2000 –Present)

American Heart Association, Fellow (2007-Present)

American College of Clinical Pharmacy, Associate Member (1995-2000)

American College of Clinical Pharmacy, Full Member (2001- 2007)

American College of Clinical Pharmacy, Fellow (2007-Present)

ACCP, Medicine Practice and Research Network, Member (2004-2010)

ACCP, Cardiology Practice and Research Network, Member (2000-Present)

American Society of Health System Pharmacists, Member (1994-Present)

American Society of Health System Pharmacists, Fellow (2009-Present)

Colorado Pharmacist’s Society, Member (1998-Present)

American Association of Colleges of Pharmacy, Member (1998 – 2004)

Kappa Psi Pharmaceutical Fraternity, Member (1991 – Present)

2. Review/Advisory Panels

AlphaMedica. Clinical Pharmacy Advisory Panel. 2008.

American College of Cardiology Foundation/American Heart Association/Heart Rhythm

Society. 2013 Guideline for the Management of Patients with Atrial Fibrillation. 2013

American College of Cardiology Foundation/American Heart Association Task Force on Expert

Consensus Documents/American Heart Association. Clopidogrel Clinical Alert. 2010.

American Association of Colleges of Pharmacy. Grant Reviewer, New Investigator Program.

2005-2007.

ARCA Discovery, Inc. Clinical Pharmacy Advisory Panel. February 2007-2009.

Association of Faculties of Pharmacy of Canada. External Referee.

New Investigator Research Award. 2009.

Astellas Pharma. Scientific Advisory Board. 2005-2008.

Astra-Zeneca. Medical Advisory Board. 2005-2008.

Bayer Corporation. Natrecor National Clinical Pharmacy Advisory Board.

1999-2001.

Biovail. Medical Advisory Board. 2004-2006.

Glaxo-Smith Kline. Clinical Pharmacy Advisory Board. 2000-2002.

Interprofessional Professionalism Collaborative. Scientific Reviewer. 2010.

Novations. Clinical Pharmacy Advisory Board: University Hospital Consortium

National Nesiritide Medication Use Evaluation. 2002-2004.

Advancement, Promotion and Tenure Committee. External Reviewer: Thomas Jefferson

University, The Ohio State, University of Kansas, Western University, Campbell University,

Texas Tech University, University of Wisconsin, University of Pittsburgh. 20004-Present.

Scios. Natrecor Pharmacy Advisory Board. 2001-2002, 2005-2006.

University of Colorado, School of Pharmacy, Intramural Grant Reviewer. Department of Clinical

Pharmacy Seed Grants. 2003.

University of Colorado, School of Pharmacy, Intramural Grant Reviewer. Department of Clinical

Pharmacy Seed Grants. 2013.

9. Publication Referee

American College of Clinical Pharmacy, Publications 2000-2014

American Journal of Cardiovascular Drugs 2000-2009

American Journal of Managed Care 2000-Present

American Journal of Geriatric Pharmacotherapy 2006-Present

American Heart Journal 2013-Present

American Pharmaceutical Association, Publications 2000-2013

American Society of Health Systems Pharmacists, Publications 2000-2010

Applied Clinical Informatics 2004-2005

Achieves of Internal Medicine 2010-Present

BMC-Public Health 2009-2010

Circulation 2010-Present

Circulation-Heart Failure 2010-Present

Clinical Drug Investigation 2000-2004

Clinical Pharmacokinetics 2010-2011

Clinical Therapeutics 2000-2005

Drugs of Today-Prous Thomson Reuters 2010-2011

Elsevier-Health: Cardiovascular Nursing 1998-2013

Expert Opinion in Pharmacotherapy 2009-2010

Expert Review in Cardiovascular Therapy 2009-2010

Heart and Lung 2013-Present

Journal of the American Heart Association 2013-Present

Journal of the American Society of Health System Pharmacists 2000-Present

Journal of Cardiac Failure 2009-Present

Journal of Clinical Pharmacology 2001-2003

Journal of Clinical Pharmacology and Therapeutics 2002-2005

Journal of Clinical Psychopharmacology 2002-2004

Journal of Clinical Toxicology 2011-Present

Journal of Heart and Lung Transplantation 2010-Present

Journal of Herbal Pharmacotherapy 2000-2003

Journal of Managed Care Pharmacy 2000-Present

Journal of Medical Case Reports 2000-2004

Nature Reviews Cardiology 2010-2011

Neuro-Psychopharmacology & Biological Psychiatry 2000-2002

Pharmacopsychiatry 2000-2002

Pharmacotherapy 1998-Present

Pharmacy Times 2000-2011

Pharmacy Today 2000-2011

Spring House Publishers, Herbal Division 1998-2010

Vascular Health and Risk Management 2000-2001

10. Journal Editorial Boards

World of Cardiology 2009-2013

Treatment Strategies-US Cardiology 2010-Present

Journal of Clinical Toxicology 2011-Present

Consultant Pharmacist 2011- Present

Progress in Transplantation 2012-Present

Journal of the American College of Cardiology-Heart Failure 2012-Present

European Medical Journal-Cardiology 2013-Present

11. Book Editor

Faculty Section Editor: Cardiology 2011-2013

Phamarmacotherapy Self Assessment Program

(PSAP) VIII, Cardiology Books 1 and 2

12. Health Policy Development

House Bill 07-1021. Colorado Prescription Drug Consumer Information and Technical

Assistance Program. Colorado Department of Health Care Policy and Financing. 2007-2008.

American College of Cardiology Foundation/American Heart Association. Health Policy

Position-Therapeutic Interchange and Substitution. 2011.

American Heart Association. American Heart Association. Statement on Drug Formularies. 2011.

13. Other Public Service

“Smoking Bans and Infants.” National Public Radio (NPR). November 2010.

“Moms, Infants, and Smoking Bans.” CBS National Radio. Charles Osgood Files. November

2010.

“When Natural is Not Always Safe.” Alumni Association-University of Denver. October 2010.

“Pregnancy in a Pill.” Denver 7 News-KMGH. May 2009.

“How to Pay for Your Medications.” Denver 9-News-KUSA. April 2009.

“Understanding Your Prescription Medications.” Retired Veterans Association. Westminster,

CO. January 2009.

Blood Pressure Screening, State Capital, Health Day at the Legislature. April 2005-2009.

Nine News Health Fair. University of Colorado Hospital. 1999-Present.

“The Dangers of Alcohol and Marijuana Use.” Red Ribbon Week, Jefferson County Gifted

Center at Westridge Elementary School, Pharmacy Week, October 2001.

“What the Ads Won’t Tell You: Dangers of Tobacco and Alcohol Use.” Red Ribbon Week,

Jefferson County Gifted Center at Westridge Elementary School, Pharmacy Week, October

2000.

“What Can A Pharmacist Do?”, Jefferson County Gifted Center at

Westridge Elementary School, Pharmacy Week, October 1999.

Blood Pressure Screening, UCHSC School of Pharmacy, National Pharmacy Week

Activities, Auraria Campus, October 1998.

N. ADVISING ACTIVITY

1. Pharmacy Residents

Anne Zegafuse 1998-1999

Jamie Nash 1998 –1999

Sherri Zerr 2002-2003

Kenneth Utz 2006-2007

Allison Mann 2009-2010

Matthew Hafermann 2010-2011

2. Pharmacy Students

Klsey McCreedy 2013-2016

Dana Ng 2013-2016

Shreaf Khattab 2013-2015

Ransom Jones 2013-2015

Michael Casias 2013-2014

Philip Leong 2013-2014

3. Student Chapter Organizations

Faculty Advisor, American Society of Health Systems Pharmacists

1998-2013. Co-advisor as of 2013-present.